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ABSTRACT 
 
LISA EILEEN STALHEIM CROSE:  Regulation and Function of the Cerebral 
Cavernous Malformation 2 Protein 
(Under the direction of Gary L. Johnson, Ph.D.) 
 
 
 Cerebral cavernous malformations (CCM) are vascular lesions of the 
central nervous system characterized as clusters of dilated, thin-walled blood 
vessels.  CCM lesions are fragile and prone to vascular leakiness and rupture, 
leading to hemorrhages that cause seizure and stroke.  Familial CCM has been 
shown to be genetically linked to three genes:  CCM1, CCM2, and CCM3.  The 
proteins encoded by these genes have no apparent catalytic activity, suggesting 
they are scaffolds to organize and localize functional protein complexes in cells.  
This scaffolding function has been appreciated for CCM2, which encodes 
Osmosensing Scaffold for MEKK3 (OSM).  CCM2 (OSM) coordinates a signaling 
complex that consists of Rac1, MEKK3, and MKK3 to activate p38 in response to 
osmotic stimuli.  The studies described here analyze the function of CCM2 in the 
context of cerebral cavernous malformations.  Using proteomic, biochemical, and 
in vivo models, we characterize CCM2 as a critical regulator of endothelial cell 
signaling and function.  We show that CCM2 binds and localizes the CCM1 
protein. The CCM2 phosphotyrosine binding (PTB) domain is necessary for a 
canonical interaction with NPxY motifs within CCM1.  We provide evidence of co-
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immunoprecipitation and fluorescence resonance energy transfer (FRET) 
between CCM1 and CCM2, implicating a common genetic and molecular 
pathway in CCM pathogenesis.  We also characterize CCM2 as a Smurf1 
binding partner.  Through a novel CCM2 PTB domain – Smurf1 HECT domain 
interaction, CCM2 recruits Smurf1 to specific locations at the plasma membrane 
where it specifically degrades RhoA.  Knockdown of CCM2 in brain endothelial 
cells leads to increased RhoA protein levels and ROCK signaling.  Functionally, 
this leads to deficiencies in cell migration, tube formation, and maintenance of a 
permeability barrier.  To determine the role of CCM2 in vivo, we used Danio rerio 
as a model for vertebrate development.  Loss of CCM2 expression leads to 
decreased blood flow due to restrictions and abnormalities of the aortic arch.  
The findings presented here indicate that CCM2 regulates protein complexes and 
signaling pathways important in endothelial cell function and provide insight into 
the molecular mechanisms involved in cerebral cavernous malformation 
pathogenesis. 
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I.  Introduction 
Cerebral cavernous malformations (CCM) are vascular lesions of the 
central nervous system characterized as clusters of dilated, thin-walled blood 
vessels.  These vascular “caverns” are surrounded by connective tissue, 
preventing innervation of the surrounding neural parenchyma (Clatterbuck et al., 
2001).  CCM lesions are fragile and prone to vascular leakiness and rupture, 
leading to hemorrhages that cause seizure and stroke (Marchuk et al., 2003; 
Plummer et al., 2005).  In the general population, it is believed that 0.5 – 1.0% 
individuals will be affected by CCM in their lifetime.   
Cavernous malformations (also known as cavernous angiomas) can occur 
sporadically or through autosomal dominant inheritance of mutations in one of 
three genes:  CCM1, CCM2, and CCM3.  Although there is incomplete 
penetrance of the CCM phenotype, this familial form accounts for over 20% of 
CCM cases.  Therefore, understanding the roles of CCM1, CCM2, and CCM3 in 
cell physiology is critical for our understanding of CCM pathogenesis.   
 
CCM1 
Mutations in CCM1 lead to truncations of the protein Krev Interaction 
Trapped 1, or KRIT1 (Sahoo et al., 1999; Zhang et al., 2000b).  To date, over 
100 germline mutations have been identified in CCM1, most involving premature 
stop codons due to nonsense, frameshift, or spice-site mutations (Cave-Riant et 
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al., 2002; Chen et al., 2002; Couteulx et al., 2002; Davenport et al., 2001; Eerola 
et al., 2001; Laberge-le Couteulx et al., 1999; Laurans et al., 2003; Lucas et al., 
2001; Marini et al., 2003; Marini et al., 2004; Musunuru et al., 2003; Sahoo et al., 
2001; Sahoo et al., 1999; Verlaan et al., 2002; Xu et al., 2003; Zhang et al., 
2000b).  It is widely believed that these mutations in CCM1 lead to loss of 
function of this gene.   
CCM1/KRIT1 had previously been identified in a yeast two-hybrid screen 
for proteins that interact with the Ras family GTPase Krev1/Rap1A.  Initial 
characterization of CCM1 found that the carboxy- terminus of CCM1 shared a 
weak homology to the Band 4.1 protein.  This region of homology would later be 
characterized as a FERM domain, based on the domains of Band four-point-one, 
Ezrin, Radixin, and Moesin.  CCM1 also contains three ankyrin domains in the 
central region of the protein, assumed to be for additional protein interactions.  
The FERM domain of CCM1 was determined to be necessary for interaction with 
Krev1/Rap1A and CCM1 itself did not bind strongly to Ras. It was speculated that 
because of its binding to Krev/Rap1A and not Ras, CCM1 could be specifically 
regulating Krev/Rap1A signaling (Serebriiskii et al., 1997).   
Following the initial study of CCM1 as a Rap1A binding protein, this data 
was contested when additional groups could not confirm this association.  In 
these studies, a longer CCM1 bait was used.  This was due to the identification 
of additional CCM1 exons at the 5’ end of the sequence, extending CCM1 by 207 
amino acids (Eerola et al., 2001; Sahoo et al., 2001; Zhang et al., 2000a).  
Surprisingly, this longer CCM1 did not associate with Krev1/Rap1A, suggesting 
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that either the amino-terminus of CCM1 masks the Krev1/Rap1A binding site, or 
previous data using the shorter CCM1 needed further confirmation (Zawistowski 
et al., 2002; Zhang et al., 2001).  The CCM1-Rap1A interaction was therefore re-
examined.  Using multiple biochemical assays, CCM1 was confirmed as a 
Rap1A binding protein, but binding was regulated by a CCM1 conformational 
change (Sophie Béraud-Dufour, 2007).  CCM1 was found to exist in an open or 
closed conformation, and this conformational change regulated Rap1A binding.  
This work confirmed the CCM1-Rap1A interaction, and resolved the discrepancy 
associated with previous studies of CCM1-Rap1A interactions.   
The CCM1-Rap1A interaction was determined to function as a mechanism 
to recruit CCM1 to endothelial cell junctions.  Endogenous CCM1 localized at 
endothelial cell junctions, as determined by co-localization with β-catenin.  
Endogenous β-catenin also associated with endogenous CCM1 by co-
immunoprecipitation.  Expression of an active form of Rap1A (Rap1A-G12V) 
increased association of CCM1 with β-catenin, while expression of an inhibitor of 
Rap1A activity (Rap1GAP) decreased association of CCM1 with β-catenin.  
Knockdown of CCM1 expression led to loss of β-catenin at cell junctions, 
increased stress fiber formation, and increased endothelial cell permeability.  
Further, expression of exogenous CCM1 was able to reverse increased 
permeability induced by expression of Rap1GAP.  Taken together, CCM1 plays 
an important role in endothelial permeability through Rap1A-mediated 
association with endothelial cell junctions (Glading et al., 2007). 
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A second binding partner for CCM1 is Integrin Cytoplasmic Adapter 
Protein-1 (ICAP1) (Zawistowski et al., 2002; Zhang et al., 2001).  ICAP1 is a 
negative regulator of β1 integrin signaling implicated in osteoblast proliferation 
and differentiation (Bouvard et al., 2007).  ICAP1 contains a Phosphotyrosine 
Binding (PTB) domain, which is responsible for its association with the β1 tail 
through a conserved Asparagine – Proline – any amino acid – Tyrosine (NPxY) 
motif (Chang et al., 1997; Zhang and Hemler, 1999).  An NPxY motif was also 
found within the amino acid sequence of CCM1 (N192-Y195), suggesting that the 
ICAP1 PTB domain could interact with this CCM1 NPxY motif.  Mutation of the 
CCM1 NPxY motif led to a decrease in ICAP1 binding demonstrated by GST 
pulldown and by liquid beta-galactosidase assay (Zawistowski et al., 2002).  
Because of the critical role of β1 integrins in endothelial cell function, it was 
hypothesized that loss of CCM1 may lead to defects in endothelial cell adhesion 
and migration through ICAP1 binding.   
The importance of the CCM1-ICAP1 interaction was defined when ICAP1 
was found to regulate the open/closed conformation of CCM1 (Sophie Béraud-
Dufour, 2007).  The CCM1 intermolecular interaction was shown to be between 
CCM1 NPxY motifs and the CCM1 FERM domain.  Presumably, this was 
occurring between the CCM1 NPxY motifs and the F3 subdomain of the CCM1 
FERM domain, which shares structural similarity to PTB domains (Calderwood et 
al., 2002).  The interaction between the CCM1 NPxY motif and CCM1 FERM 
domain was lost upon addition of ICAP1.  Furthermore, in GST-pulldown 
experiments, CCM1, ICAP1, and Rap1A were found to exist as a ternary protein 
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complex.  Based on these data, it was suggested that ICAP1 could induce the 
open conformation of CCM1 by binding CCM1 NPxY motifs.  In the open 
conformation, CCM1 would then be available to interact with Rap1A.  Based on 
our current knowledge of CCM1 as a Rap1A effector, this would imply that ICAP1 
could act to regulate the availability CCM1 as a Rap1A effector to regulate cell 
junctions (Figure 1.1).   
 
CCM2 
MGC4607 was identified as the CCM2 gene in 2003.  In nine families 
analyzed, eight unique mutations, predominantly deletions leading to frameshift 
changes, were found within the CCM2 gene.  Based on the amino acid sequence 
of CCM2, a PTB domain was identified in the amino-terminus of CCM2.  
Interestingly, the amino-terminal end of CCM2, including the PTB domain, 
harbored all of the mutations identified in the cohort (Liquori et al., 2003).  Further 
analysis identified more pronounced genetic lesions in CCM2 patients, including 
large deletions of almost the entire CCM2 gene (Liquori et al., 2007). 
 Concomitant with the discovery of MGC4607 as the CCM2 gene, the 
mouse homolog of CCM2 was characterized as Osmosensing Scaffold for 
MEKK3 (OSM).  Although there are many upstream MAPKKKs that activate p38, 
MEKK3 was found to be specifically involved in hypertonic activation of this 
pathway (Uhlik et al., 2003).  MEKK3 knockdown cells were found to be deficient 
in their activation of p38 in response to sorbitol.  OSM was found to be an 
important regulator of this pathway.  Identified in a yeast two-hybrid screen using 
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MEKK3 as bait, OSM was found to associate with MEKK3 and MKK3 by 
immunoprecipitation.  Expression of OSM with MEKK3 was found to 
synergistically increase MKK3 phosphorylation.  Further, joint knockdown of 
OSM with MEKK3 synergistically decreased activation of p38 in response to 
sorbitol treatment.  Endogenous OSM was found to associate with actin ruffles, 
and sorbitol treatment of COS-7 cells induced OSM and MEKK3 association in 
live cells by fluorescence resonance energy transfer (FRET).  The GTPase Rac1 
was also found to associate with OSM, and this association was induced by 
sorbitol treatment in live cells.  Therefore, it was hypothesized that the signaling 
module of Rac1-OSM-MEKK3-MKK3 to activate p38 was analogous to the Hog1 
osmotic signaling pathway in Saccharomyces cerevisiae (Uhlik et al., 2003). 
In response to high osmotic conditions, cells rapidly lose water and shrink.  
Yeast counter this loss of water by accumulating intracellular glycerol through 
closure of glycerol channels and up-regulation of genes for glycerol synthesis.  
This is in part coordinated by the Hog1p mitogen activated protein kinase 
(MAPK) signaling pathway.  In response to extracellular hyperosmotic stress, an 
osmotic signaling complex consisting of Cdc42p, Ste20p, Ste50p and Ste11p is 
recruited to the plasma membrane.  Ste50p recruits the p21-activated kinase 
Ste20p to the MAP kinase kinase kinase (MAPKKK) Ste11p.  Ste11p then 
phosphorylates and activates Pbs2 (MAPKK) which phosphorylates Hog1p.  
Hog1p is then translocated to the nucleus where it regulates gene expression 
(both positively and negatively) by phosphorylation of transcription factors.  Out 
of all the genes that are upregulated in response to hyperosmotic stress, only 
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20% of these genes are fully Hog1p-dependent, based on Hog1-deficient cells.  
Yet, the genes that are fully Hog1p-dependent include genes that are the most 
strongly upregulated in response to hyperosmotic stress (Hohmann et al., 2007; 
Willem H Mager, 2002).  Therefore, the Hog1p pathway is necessary for osmotic 
adaptation, and this pathway is coordinated by Ste50p, the OSM homolog 
(Figure 1.2). 
Since OSM is the mouse homolog of CCM2, the MEKK3-p38 signaling 
pathway could therefore be involved in CCM pathology.  Indeed, MEKK3 and p38 
knockout animals have defects in vascularization in utero (Adams et al., 2000; 
Yang et al., 2000).  However, if deficiencies in p38 signaling lead to CCM is not 
known.   
 
CCM3 
 The CCM3 gene was documented in 2005 by two independent groups 
(Bergametti et al., 2005; Guclu et al., 2005).  Similar to CCM1 and CCM2, most 
mutations in the CCM3 gene led to premature stop codons or gene deletions.  
The CCM3 gene encodes the protein Programmed Cell Death protein 10.  
CCM3/PDCD10 was first identified in a screen for genes upregulated in the 
human myeloid cell line TF-1 upon apoptotic induction.  Analysis of the primary 
structure of CCM3 does not identify any functional domains.  CCM3 is 
ubiquitously expressed and is highly conserved, from Caenorhabditis elegans to 
human.   
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 CCM3 is a binding partner for Mammalian Sterile Twenty-like 4 (MST4).  
MST4 is a Ste20-like kinase capable of activating the ERK MAPK pathway and 
promoting cell proliferation (Lin et al., 2001).  CCM3 and MST4 co-localize in 
distinct perinuclear regions in HeLa cells.  Expression of exogenous CCM3 in 
PC-3 cells demonstrated that CCM3 could also induce cellular proliferation.  
RNAi-medated knockdown of CCM3 inhibits normal cellular proliferation as well 
as MST4-induced proliferation.  CCM3 expression increased phosphorylation of 
ERK, which could be abrogated by treatment with MST4 siRNA.  Therefore, 
CCM3 and MST4 could act in a common pathway to activate ERK signaling (Ma 
et al., 2007).  Although these studies demonstrate a clear role for CCM3 and 
MST4 in ERK signaling and cell proliferation, to date there has been no 
examination of CCM3 in endothelial cells.   
 
Animal models of CCM 
Mus musculus 
In order to understand the role of the CCM genes in development and 
angiogenesis, gene knockout models were generated for CCM1.  The first mouse 
CCM1 knock-out was a CCM1 gene-trap model, generated by insertion of the 
beta-galactosidase gene in CCM1 exons 6-7.  The resulting CCM1-null 
homozygotes led to embryonic lethality at E8.5-9.5 with predominant vascular 
defects.  At this stage, these embryos displayed dilated vessels of the cephalic 
mesenchyme and an undeveloped yolk sac.  The dorsal aortae of these embryos 
also exhibited a distended morphology that was suggested to be due to 
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differences in proliferation rates of the endothelial cells in this region.  
Furthermore, these vessels were defective in their ability to recruit smooth 
muscle cells and expressed significantly less EphrinB2, Dll4, and Notch4, which 
are arterial markers.  It was suggested that CCM1 was necessary for arterial 
identity and morphogenesis (Whitehead et al., 2004).   
These studies were the first to examine the physiological importance of 
CCM1 in vascular development.  However, this model was not adequate for 
modeling CCM pathogenesis.  Human CCM patients are not homozygous for 
mutations in CCM genes.  For all CCM genes identified, patients are 
heterozygous for familial mutations in CCM genes.  Therefore, in order to 
determine if the CCM1 knock-out mouse was a proper animal model for CCM, it 
was important to determine if mice that were heterozygous for the CCM1 gene 
had an increased chance of CCM formation.  In 20 adult mice heterozygous for 
CCM1 (aged 8 weeks to 14 months), no brain lesions were seen by gross 
dissection.  This suggested that a “two hit” genetic model (described below) may 
be needed to generate a proper mouse model for CCM.  With this in mind, a 
CCM1+/- Trp53-/- double knock-out mouse line was generated.  Because of the 
increased rate of mutation in a p53-null background, it was believed that this 
could induce somatic muations and increase the prevalence of CCM lesions.  
This rationale led to brain vascular malformations in five of the nine CCM1+/- 
Trp53-/- mice analyzed.  No vascular malformations were found in CCM1+/- 
Trp53+/- mice or CCM1+/+ Trp53-/- mice.  However, no loss of heterozogosity at 
CCM1 was observed, nor were any mutations in Trp53 found in any CCM 
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patients (Plummer et al., 2004).  This suggested that a second mutation, a 
somatic mutation, was necessary to model CCM1 pathogenesis in mice.   
Interestingly, CCM2 heterozygous gene-trap mice displayed cerebral 
hemorrhage without knockout of Trp53.  The penetrance of such lesions was low 
(about 10% of adult animals), but the morphology of the lesions was similar to 
those seen in CCM1+/- Trp53-/- knockout mice.  Similar to CCM1, the CCM2 
knockout was generated by insertion of a gene-trap vector into the CCM2 gene.  
The insertion of βGeo into exon 6 of CCM2 caused a deletion of 45 base pairs of 
this exon leading to a transcript that contained the amino terminus of CCM2 
through the PTB domain, but truncation of the carboxy terminus.  Similar to 
CCM1 knockout mice, CCM2 homozygous null mice died during gestation.  Due 
to the low penetrance of lesions it was hypothesized that a two-hit model was 
also likely for a mouse model of CCM2 (Plummer et al., 2006).  To date, no 
mouse models of CCM3 have been published.  These mouse models show that 
CCM can be modeled in mice; however the molecular events that trigger CCM 
lesion formation are not known.   
 
Caenorhabditis elegans 
 The C. elegans homologue of CCM1, KRI-1, was identified in a screen for 
genes involved in organism longevity.  In this model, longevity is regulated by 
intestinal-reproductive tract interactions.  A key signaling pathway involved in 
reproductive system regulation of longevity is the IGF-1-Akt pathway.  IGF-1 
signaling activates Akt leading to phosphorylation of the transcription factor 
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FOXO1.  The FOXO1 homolog in C. elegans is DAF-16.  Phosphorylation of 
DAF-16 sequesters it in the cytoplasm, preventing its ability to regulate gene 
expression.  Loss of KRI-1 expression in the sterile longevity model suppressed 
longevity.  Examination of intestinal DAF-16 showed that in KRI-1 RNAi treated 
animals DAF-16 had reduced nuclear localization.  This nuclear localization 
defect was independent of DAF-16 phosphorylation, as the mislocalization could 
be overcome by expression of a DAF-16 whose Akt phosphorylation sites were 
mutated to alanine.  This suggested a role for KRI-1 in DAF-16 localization, either 
by preventing Akt phosphorylation of DAF-16, or through an independent 
localization function of KRI-1 (Berman and Kenyon, 2006).  However, the 
mechanism of this regulation has not been determined, either in C. elegans or 
mammalian systems.   
 
CCM cell of origin 
 CCM lesions are predominantly in the central nervous system.  What 
causes lesions to specifically occur in the CNS?  As neural, astrocytic, and 
pericytic innervations regulate the cerebral microvasculature (Figure 1.3), the cell 
of origin for CCM has been relatively controversial.  An initial study of the CCM1 
expression pattern in the mouse embryo suggested that CCM1 was 
predominantly expressed in neural cells but not endothelial cells.  Using in situ 
hybridization, CCM1 mRNA was ubiquitously detected in E7.5-E9.5 mouse 
embryos.  Later term embryos displayed predominant nervous system 
expression of CCM1, as well as epithelial tissues such as lung and intestine.  
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The tissues of the cardiovascular system showed embryonic expression of 
CCM1 in the heart and aorta, but not in capillaries.  Furthermore, in adult human 
and mouse tissues, CCM1 was expressed in the neuronal layers of the cerebral 
cortex, the brainstem, and epithelial tissues.  CCM1 expression was not detected 
in the adult vasculature (Denier et al., 2002).  Similar expression patterns were 
observed for CCM2 RNA.  In adult murine brain tissue, CCM2 expression was 
strong in neuronal populations but undetectable in brain vascular endothelium 
(Plummer et al., 2006).  This suggested that cells other than endothelium may be 
involved in the pathogenesis of CCM.   
 A more complex view of CCM gene expression in the mouse was 
observed by Petit and colleagues in 2005.  By in situ hybridization, strong 
expression of CCM1, CCM2, and CCM3 was observed in the developing nervous 
system, including the ventricular zone, intermediate zone, cortical plate and 
ganglionic eminence in the brain, as well as the spinal cord.  Similarly, neuronal 
cell layers at P8 and P19 displayed strong expression of the 3 CCM genes as 
well as the motor neurons of the grey matter of the adult spinal cord.  In the 
cardiovascular system, CCM1, CCM2, and CCM3 were expressed in the heart, 
aorta, and cardinal vein at E10.5, and at E14.5 this expression persisted in the 
superior vena cava and aorta, internal carotid, and vertebral and basilar arteries.  
Examination at P0 showed loss of expression in these regions.  In the cerebral 
vasculature, weak or no expression was observed prenatally, but postnatally 
weak expression was observed for CCM2 and CCM3 at P0 and P8.  This 
expression was lost by P19.  Altogether, these experiments suggested restricted 
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and transient expression of CCM genes in the cerebral vasculature and 
predominant expression of these genes in neuronal cells.  In regards to CCM 
pathogenesis, a prominent role for perenchymal cells and perenchymal-
endothelial cell interactions could not be discounted (Petit et al., 2006).  
 CCM is believed to be due to endothelial defects, based on ultrastructural 
data that shows defective cell to cell contacts within CCM lesions (Clatterbuck et 
al., 2001).  This is supported by the CCM1 knockout mouse, which displayed 
vascular abnormalities but normal brain development (Whitehead et al., 2004).  
However, mRNA expression data implies a potential role for CCM genes in 
neuronal cells.  The cellular interactions within the cerebral vasculature are 
complex, including a prominent role for neuronal, astrocytic, and pericytic 
innervation in the microvasculature of the brain (Figure 1.3).  The importance of 
these supporting cells has become clearer through use of conditional knockout 
animals.  One example of the importance of the cerebrovascular support cells is 
with the αvβ8 integrin.  Knockout of the αv integrin leads to embryonic (E10.5-
E12.5) and perinatal lethality due to intracranial and intestinal hemorrhage.  The 
αv-null embryos displayed normal vascular patterning and vascularization of the 
placenta; however, at E11.5-E12.5 blood vessels within the brain were dilated 
and distended.  This led to subsequent hemorrhage (Bader et al., 1998).  The 
mouse knockout for the β8 integrin displayed a similar phenotype, with lethality 
occurring due to insufficient vascularization of the yolk sac and placenta or 
intracerebral hemorrhage from distended blood vessels (Zhu et al., 2002).  
Elegant studies done by McCarty et. al, subsequently showed that conditional 
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knockout of the αv integrin in endothelial cells (using Tie2-Cre) did not lead to 
intracerebral hemorrhage, but knockout of the αv integrin in astrocytes (using 
GFAP-Cre) or neurons and astrocytes (using Nestin-Cre) caused intracerebral 
hemorrhage (McCarty et al., 2005).  Further, the endothelial conditional knockout 
of β8 integrin displayed no cerebral hemorrhages with but did display cerebral 
hemorrhages in a neural-astrocytic conditional knockout model.  To further 
elucidate what cell type is involved in the cerebral hemorrhages, a β8 integrin 
conditional knockout for postmitotic neurons (using Nex-Cre) was used, which 
did not cause cerebral hemorrhage (Proctor et al., 2005).  Taken together, these 
studies suggested that the astrocytic interactions with endothelial cells were the 
cause of cerebral hemorrhage.  Indeed, conditional β8 integrin knock out mice 
with hemorrhages had disorganized cortical glia and endothelial cells, and αvβ8 
integrin was found to be localized on glial cell processes in wild type mice 
(McCarty et al., 2005; Proctor et al., 2005).  As CCM is a disease predominantly 
manifested in the blood vessels of the central nervous system, similar neural, 
glial, and endothelial interactions may prove important in the pathogenesis of the 
disease.  Ideally, similar conditional knockout studies in mice will be performed 
with CCM1, CCM2, and CCM3 to elucidate these mechanisms.   
 
The two-hit hypothesis  
Familial CCM shows incomplete penetrance.  In humans, there is lesion 
formation in ~60% of individuals that are genetically heterozygous for inherited 
mutations in CCM genes (Labauge et al., 2007).  In mouse models there is a 
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near absence of lesions in animals that are heterozygous for CCM1 or CCM2 
expression.  When crossed into a Trp53-/- background to induce genetic 
instability and somatic mutations, mice heterozygous for the CCM1 gene-trap 
allele had significantly more CCM lesions than those without Trp53 knockout 
(Plummer et al., 2004).  Therefore it was hypothesized that there must be a 
second genetic hit associated with CCM lesion formation, analogous to what is 
observed in retinoblastoma (Goodrich and Lee, 1993).   
Recent studies definitively prove the “two hit” hypothesis for induction of 
CCM.  A recent study was able to demonstrate that bi-allelic mutations in CCM 
genes existed in endothelial cells from CCM lesions.  These somatic mutations 
were not seen in cells surrounding the lesion (Akers et al., 2009).  Further 
support of the two hit hypothesis was a study of CCM protein immunoreactivity in 
CCM lesions.  Loss of immunoreactivity of CCM1, CCM2, or CCM3 was 
observed in endothelial cells from CCM lesions with the corresponding mutations 
in CCM1, CCM2, or CCM3, but not adjacent vascular beds (Pagenstecher et al., 
2009).  These studies show that in human CCM, mutation of both alleles and 
subsequent loss of expression of CCM1, CCM2, or CCM3 are critical steps in 
CCM pathogenesis.   
 
CCM2, structure and function 
 The CCM2 protein contains a PTB domain in the amino terminal region.  
By homology, the CCM2 PTB domain is most similar to the Dab-like PTB 
domains (Uhlik et al., 2005).  Dab-like PTB domains contain a PH-domain 
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superfold, which is a structural feature common to all PTB domains.  As the 
name implies, the PH domain superfold is similar to the prototypical 
phospholipid-binding PH domain.  Indeed, numerous PTB domains have been 
shown to bind to phospholipids, likely regulating their cellular localization.   
 A distinguishing feature of Dab-like PTB domains is their peptide binding 
specificity.  The canonical binding motif for PTB domains is Asn-Pro-X-Tyr 
(NPxY), which forms a β turn.  The prototypical PTB domains of Shc and IRS-1 
bind to these NPxY motifs when the tyrosine is phosphorylated.  Dab-like PTB 
domains bind to unphosphorylated tyrosines in this motif, and in some cases 
prefer phenylalanine (NPxF).  Therefore, interactions between Dab-like PTB 
domains and their interacting peptides are due to extensive hydrophobic contacts 
and hydrogen bonds within and surrounding the NPxY or NPxF motif.   
 Interestingly, the CCM2 PTB domain is most similar to the ICAP1 PTB 
domain, which binds to CCM1 (Uhlik et al., 2005).  Thus, there is the potential 
that CCM2 could be utilizing its PTB domain to bind to CCM1.  This would link 
CCM1 and CCM2 genetically and molecularly, suggesting that a common 
signaling pathway is involved in CCM pathogenesis. 
 
Objectives of this project 
CCM signaling pathways 
 Examination of the primary sequence of CCM1, CCM2, and CCM3 
illustrates that these three proteins do not contain any identifiable catalytic 
domains.  However, they do contain protein interaction domains (Figure 1.1).  We 
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hypothesize that CCM pathogenesis could be caused by improper protein 
scaffolding and subsequent cell signaling abnormalities.  Since mutations in 
CCM1, CCM2, or CCM3 all lead to the same disease, there is the potential that 
CCM1, CCM2, and CCM3 are involved in a common signaling pathway.  This 
sole pathway may be responsible for CCM.  It is also possible that individual 
pathways mediated by CCM1, CCM2, or CCM3 could lead to similar phenotypes.  
In order to understand these signaling pathways, we would like to determine 
proteins that interact with CCM2.  We can then begin to elucidate the functions of 
these proteins both in normal cell physiology and how loss of these proteins 
could lead to CCM.  We plan to utilize proteomic strategies to find binding 
partners for CCM2.   
 CCM proteins also need to be examined in the context of cerebral 
microvascular cells.  To date, studies that have utilized endothelial cell culture 
systems have used either HUVECs or BAECs.  These are good models for 
primary endothelial cells, but different models are needed for study of CCM.  The 
endothelial cells of the brain are specialized to maintain the blood brain barrier, 
and their physiology is quite different from other endothelial cells.  Because 
cerebral cavernous malformations lesions frequently occur in the central nervous 
system, the most logical cell system to use would be cerebral endothelial cells.  
Therefore, we plan to examine role of endogenous CCM2 in brain endothelial 
cells using RNAi.   
 
CCM2 protein function in vivo 
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 Loss of CCM2 expression in a mouse gene-trap model leads to embryonic 
lethality at E9.5.  Such early embryonic lethalities are difficult to study, and 
mouse colony breeding and maintenance for examination of embryonic lethalities 
are costly and time consuming.  Since CCM2 is necessary for embryonic 
development, we plan to utilize a common model for vertebrate development, 
Danio rerio.  The zebrafish developmental model has many advantages when 
compared to mouse.  Zebrafish undergo major developmental processes in a 
short period of time.  By 72 hours post fertilization (hpf), zebrafish embryos have 
undergone major morphogenic events for the majority of organ systems, allowing 
rapid screening for defects associated with early embryonic lethalities.  Zebrafish 
are amenable to genetic manipulation by translational-blocking morpholios.  
What many consider the greatest advantage of the zebrafish model is that 
embryo development occurs externally and embryos are optically clear.  We will 
be examining the role of CCM2 in vertebrate development by using CCM2 
translational-blocking morpholinos and characterizing defects associated with 
CCM2 loss.   
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Figure 1.1:  Domain structure, interacting proteins, and known function of CCM1, 
CCM2, and CCM3.  CCM1 exists in a closed or open conformation, which is 
regulated by ICAP1.  This can regulate association of CCM1 with Rap1A.  CCM2 
associates with Rac1, MEKK3, and MKK3 to activate p38 in response to osmotic 
stress.  CCM3 has no identifiable domains, but has been shown to associate with 
the MST4 kinase to activate Erk signaling pathways.  
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Figure 1.2:  Osmotic signaling to p38 via OSM/MEKK3 in mammals is analogous 
to signaling to Hog1 via STE50/STE11 in yeast.  Rac1 and OSM associate at the 
plasma membrane.  Upon hyperosmotic stimulus, OSM coordinates a signaling 
complex of MEKK3 and MKK3 to activate p38.  Yeast utilizes a signaling 
complex of Cdc42, STE50, STE11, and Pbs2 to activate Hog1 in response to 
osmotic stimuli.   
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Figure 1.3:  The neurovascular unit.  The microvasculature of the central nervous 
system contains endothelial cells supported by pericyte and astrocytic 
innervations.  Endothelial cells maintain tight junctions with each other as well as 
complex interactions with supporting cells.  The cerebral vasculature also 
receives input from interneurons through astrocytic processes.  Adapted from 
(Abbott et al., 2006). 
 
II.  Materials and Methods 
 
Chapter 3 
Plasmids and cell culture 
Full-length cDNAs for human CCM1 and ICAP1α were isolated by RT–
PCR from HUVEC RNA, N-terminally FLAG-tagged by PCR and subsequently 
cloned into the mammalian expression vector pRK5.  Full-length cDNA for CCM2 
was N-terminally FLAG-tagged by PCR using human IMAGE Consortium clone 
3501896 was used as template and subsequently cloned into pRK5.  For CFP 
and YPF fusion proteins, full-length human CCM1 cDNA was inserted in-frame to 
the coding sequence of EYFP of pEYFPC1 (Clontech) and full-length human 
ICAP1α cDNA was inserted in-frame to the coding sequence of ECFP of 
pECFPC1 (Clontech).  CFP-CCM2 and hemagglutinin (HA)-MEKK3 have been 
described previously (Uhlik et al., 2003).  Missense mutations were made using 
QuickChangeTM (Stratagene) site-directed mutagenesis kit and confirmed by 
sequencing.  
293T cells and COS-7 cells were maintained in Dulbecco's modified Eagle 
medium (DMEM, Invitrogen)/10% fetal bovine serum (FBS, Invitrogen) and 
supplemented with amphotericin B (GensiaSicor Pharmaceuticals) and 
penicillin/streptomycin (Invitrogen) at the manufacturers' recommended 
concentrations.  
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Immunoprecipitation and western blotting 
For co-immunoprecipitation assays, 293T cells were transfected with the 
constructs listed using FuGene6TM reagent (Roche). Transfected 293T cells or 
MEFs were lysed in a buffer containing 0.6% Triton X-100, 137 mM NaCl, 10% 
glycerol and 20 mM Tris pH 7.4 supplemented with CompleteTM protease inhibitor 
tablets (Roche). About 500 µg of cell lysate was incubated with a rabbit 
polyclonal CCM2 (OSM) antibody (Uhlik et al., 2003) with gentle rocking at 4°C 
for 2 hours followed by incubation with protein G-sepharose 4B beads 
(Amersham) at 4°C for 1 hour.  The beads were washed five times with lysis 
buffer, boiled for 5 min in SDS-loading buffer and resolved by SDS–PAGE.   
For western blotting, the following antibodies were used:  anti-FLAG 
antibody (M2, Sigma), anti-HA antibody (Sigma), and affinity-purified anti-CCM1 
antibody (Bethyl Laboratories, Inc.).  
 
Fluorescence resonance energy transfer 
For live-cell fluorescence microscopy and CFP-YFP FRET experiments, 
COS-7 cells were grown on 25 mm round glass coverslips.  Cells were 
subsequently transfected using Lipofectamine PlusTM (Invitrogen). After 24 hours, 
cells were placed in a media-filled imaging chamber (Molecular Probes) at room 
temperature. Cells were treated with 0.2 M sorbitol for the indicated times. CFP-
YFP FRET image acquisition and analysis were performed by the three-filter 
micro-FRET image subtraction method as described previously (Sorkin et al., 
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2000).  Briefly, images for YFP excitation/YFP emission, CFP excitation/CFP 
emission and CFP excitation/YFP emission (raw FRET) were obtained using an 
Axiovert 200M microscope from Zeiss (Germany) and imaging software from 
Intelligent Imaging Innovations (Denver, CO).  Background-subtracted YFP and 
CFP images were then fractionally subtracted from raw  FRET images on the 
basis of measurements for CFP bleed-through (CFP-CCM2=0.55 and CFP-
CCM2 F217A=0.52) and YFP cross-excitation (YFP-CCM1=0.021 and YFP-
CCM1 N192A=0.024). This fractional subtraction generated corrected FRET 
images (FRETC) that function as visual representations of interacting proteins.  
 
MEF isolation 
E10.5 primary MEF cultures were established from wild type embryos and 
littermate embryos heterozygous for a LacZ gene trap insertion in the mouse 
Ccm2 gene (cell line RRG051, Bay Genomics, allele designation 
Ccm2Gt(pGt0Lxf)1Dmar).  Cells were maintained in Iscove's modified Dulbecco's 
medium (IMDM, Invitrogen)/10% FBS (Invitrogen) and supplemented with 
penicillin/streptomycin (Invitrogen) and amphotericin B (GensiaSicor 
Pharmaceuticals) at the manufacturers' recommended concentrations.  
Established MEF cell lines were genotyped by PCR using the following primers: 
5'-CATCCCTGTCTGGGAACCTA-3' (CCM2 intron 6, reverse), 5'-
TCTAGGACAAGAGGGCGAGA-3' (gene trap, reverse) and 5'-
GAAGAGTTGTGCTCCCTGCT-3' (CCM2 exon 6, forward).  
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MAPK activation assay 
Spontaneously immortalized wild type and CCM2+/– MEFs were serum-
starved in OptiMEMTM (Invitrogen) overnight.  Cells were then treated with 0.2 M 
sorbitol or 10 µg/ ml anisomycin for the indicated times and harvested in lysis 
buffer containing 0.6% Triton X-100, 137 mM NaCl, 10% glycerol and 20 mM Tris 
pH 7.4 supplemented with CompleteTM protease inhibitor tablets (Roche).  Fifty 
µg of cell lysate was resolved by SDS–PAGE.  For western blotting, anti-p38 
MAP kinase (Santa Cruz Biotechnology, sc-7149) and anti-phospho-p38 MAP 
kinase (Thr180/Tyr182, Cell Signaling, #9211) were used.  Phosphorylated p38 
was quantified using densitometry and normalized to levels of total p38 to yield 
an activation index. Fold induction was calculated as the activation index of the 
sample divided by the activation index of the untreated sample.  For add-back 
experiments, CCM2+/– MEFs were transfected with pRK5-FLAG-CCM2 using the 
Amaxa NucleofectorTM.  Cells were used 24 hours post-transfection for p38 
activation experiments.  
 
Immunofluorescence 
COS-7 cells were grown and transfected on fibronectin-coated coverslips 
(Becton Dickinson).  Cells were washed with phosphate-buffered saline (PBS) 
and subsequently fixed for 14 minutes in 3% paraformaldehyde/3% sucrose/PBS, 
washed three times with PBS and permeabilized for 6 min in 0.1% Triton X-
100/PBS.  Coverslips were washed an additional three times and blocked for 30 
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minutes in a blocking solution consisting of DMEM containing 10% goat serum. 
Coverslips were then incubated for 2 hours at room temperature with anti-FLAG 
antibody (M2, Sigma) diluted in blocking solution. After washing with PBS, 
coverslips were incubated for 1 hour at room temperature with goat anti-mouse 
antibody conjugated to AlexaFluorTM 594 (1:1000, Molecular ProbesTM, 
Invitrogen). After final washes with PBS, coverslips were mounted with ProLong 
GoldTM antifade reagent (Molecular ProbesTM, Invitrogen). 
 
Chapter 4 
Zebrafish husbandry 
Wild-type AB* Danio rerio were handled in accordance with IACUC 
approved protocols.  Embryos were obtained from natural spawning.  Embryos 
were raised in 30% Danieau solution (17 mM NaCl, 0.21 mM KCl, 0.12 mM 
MgSO4, 0.18 mM Ca(NO3)2, 1.5 mM HEPES pH 7.6) and incubated at 28.5º C.   
 
Morpholino injection:  
Morpholinos were purchased from Gene Tools (Philomath, OR).  
Morpholinos were designed to the translational start site of the Danio rerio CCM2 
gene.  Two CCM2-specific morpholinos (MO) were used: MO #1: 
ATCTAATACAGCGAAAATGAAGAGC, MO #2: 
ATTTGTACGTAGAGATGGAGGAGGA, underlined ATG is translational start 
site).  Morpholinos were diluted to 2 ng/nL and 5 nL were used per injection, 
unless otherwise specified.  As a control, 1X Danieau solution was used for 
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injection (57 mM NaCl, 0.7 mM KCl, 0.4 mM MgSO4, 0.6 mM Ca(NO3)2, 5 mM 
HEPES pH 7.6).  Embryos were injected between the 1- and 4- cell stages.   
 
DAF2-DA labeling 
 The fluorescent nitric oxide (NO) indicator 4,5-diaminofluorescein 
diacetate (DAF-2DA) was a gift from Dr. Margaret Kirby (Duke University).  Live 
embryos were incubated in 10 μM DAF-2DA for 4 hours in the dark at 28.5º C.  
After incubation, embryos were then euthanized and imaged for DAF2-DA 
fluorescence.   
 
Blood flow measurements 
In silico microangiography was performed as previously described 
(Malone et al., 2007). 
 
Chapter 5 
Cell culture 
HEK293 and COS-7 cells were maintained in Dulbecco’s modified Eagle 
medium (DMEM, Gibco) supplemented with 10% fetal bovine serum (FBS, 
Gibco) and penicillin/streptomycin (Gibco).  Microvascular brain endothelial cells 
(bEND.3) cells were purchased from ATCC and also cultured in DMEM 
supplemented with 10% FBS and penicillin/streptomycin.  Mouse embryonic 
endothelial cells (MEECs) were cultured in DMEM supplemented with 3% FBS 
and penicillin/streptomycin.  Transfection of HEK293 and COS-7 was done using 
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Lipofectamine (Invitrogen) according to the manufacturer’s instructions.  Human 
umbilical vein endothelial cells (HUVEC) and EBM-2 growth medium were 
purchased from Lonza.  HUVECs were used below passage five.   
  
Antibodies 
Western blotting was performed using the following antibodies:  polyclonal 
anti-FLAG (F7425, Sigma), monoclonal anti-M5 FLAG (Sigma), polyclonal anti-
HA (sc-805, Santa Cruz), monoclonal anti-HA (12CA5), anti-MEKK3 (#1673-1, 
Epitomics), anti-CCM2 (described in (Uhlik et al., 2003)), anti-GFP (sc-8334, 
Santa Cruz), anti-Smurf1 (#2174, Cell Signaling), anti-Erk2 (sc-154, Santa Cruz), 
anti-ubiquitin (sc-8017, Santa Cruz), anti-MEKK2 (described in (Kesavan et al., 
2004)), anti-RhoA (#05-822, Millipore), anti-Rac1 (#05-389, Millipore), donkey 
anti-Rabbit (Jackson Immunoresearch), and sheep anti-Mouse (GE).  For 
immunofluorescence, the following reagents were used:  anti-phospho (Ser19)-
myosin light chain 2 (#3671, Cell Signaling), rhodamine-phalloidin (Molecular 
Probes), FITC Donkey anti-rabbit (Molecular Probes), and DAPI (4′,6′-diamidino-
2-phenylindole; 0.04 ng/ml). 
 
Plasmids 
pRK5 HA-CCM2, pECFP-CCM2, pECFP-CCM2 F217A, pCMV5 HA-
MEKK3, and pCMV5 HA-MEKK2 have been described previously (Fanger et al., 
1997; Uhlik et al., 2003; Zawistowski et al., 2005).  pCMV5 Flag-Smurf1 and 
pCMV5 Flag-Smurf1 C699A were gifts from Dr. Jeff Wrana (Samuel Lunenfeld 
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Research Institute, Mount Sinai Hospital).  pCMV Myc-RhoA was a gift from Dr. 
Keith Burridge (University of North Carolina).  pLL5.0 was a gift from Dr. Jim 
Bear (University of North Carolina).  pCMV5B Flag-Smurf2 C716A and 
pGEX4T1-Smurf1 C699A were purchased from Addgene (Addgene plasmids 
11747 and 13503, respectively).   
pcDNA Flag-Smurf1ΔHECT and pcDNA Flag-Smurf1 HECT were 
constructed by amplifying Smurf1 (bp 28-1104 for Smurf1ΔHECT, bp 1105-2274 
for Smurf1 HECT) by PCR from pCMV5 Flag-Smurf1 using Smurf1-specific 
primers engineered with flanking HindIII restriction sites.  The resulting PCR 
products were digested with HindIII (New England Biolabs) and ligated into the 
HindIII site of pcDNA3.  Smurf1 missense mutants were generated using the 
Quikchange Mutagenesis Kit (Stratagene) according to the manufacturer’s 
instructions.  Plasmids were confirmed by DNA sequencing (UNC-CH Genome 
Analysis Facility). 
 
RNAi 
pLKO.1 and pLKO.1 CCM2 shRNA plasmids were purchased from Open 
Biosystems.  293T cells were set in 6-well plates and transfected with lentiviral 
packaging vectors (1 μg each) and either pLKO.1 or pLKO.1 CCM2 shRNA 
plasmids (1.2 μg each).  At 24 hours post transfection, the media was removed 
and fresh 10% FBS/DMEM was placed on the transfected cells.  At 48 hours post 
transfection, the virus-containing supernatant was removed from the 293T cells 
and filtered through a 0.45 μM filter (Whatman).  Polybrene (10 μg/mL final 
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concentration) was added before applying the supernatant to bEND.3 or MEEC 
cells set in 6-well plates.  At 24 hours after the final infection, cells were either 
used for experiments or selected with 2 ug/mL puromycin for 2 days. 
FLAG-CCM2 pulldown 
Flag-CCM2 pulldown experiments were done exactly as described in 
(Hilder et al., 2007). 
 
Immunoprecipitation and Western blotting 
Cells were washed once with PBS and subsequently lysed on ice in 1% 
NP-40, 20 mM Tris at pH = 7.5, 100 mM NaCl, 10% glycerol, 0.1 mM EDTA, 0.1 
mM EGTA 10 μg/mL leupeptin, 2 μg/mL aprotinin, 1 mM Na3VO4, 1 mM 
phenylmethylsulfonyl fluoride.  Cell lysates were cleared by centrifugation for 10 
minutes at 4º C.  Proteins were resolved by SDS-PAGE on either 8% or 12% 
polyacrylamide gels and subsequently transferred to nitrocellulose.   
For immunoprecipitation, 300-500 μg of protein lysate was incubated with 
3-5 μg of either anti-FLAG (F7425, Sigma) or anti-HA (sc-805, Santa Cruz) for 2 
hours at 4º C with gentle rocking.  40 μL of a 1:1 dilution of Protein G Separose 
(Invitrogen) was added and incubated for another hour at 4º C.  Sepharose 
beads were then washed five times with lysis buffer and boiled for five minutes in 
SDS loading buffer before resolving the immunoprecipitated proteins by SDS-
PAGE.   
 
Immunofluorescence 
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COS-7 cells were grown and transfected on square coverslips.  bEND.3 
cells were grown on Matrigel-coated glass coverslips (1:50, BD Biosciences) and 
subsequently washed with PBS and fixed for 14 minutes with 3% 
paraformaldehyde/3% sucrose in PBS.  Cells were then permeabilized for 6 
minutes with 0.1% Triton X-100 in PBS.  After blocking in 10% donkey 
serum/DMEM, coverslips were incubated in primary antibody diluted in blocking 
buffer for 2 hours at room temperature.  Coverslips were washed with PBS and 
incubated with secondary antibody and DAPI for 1 hour at room temperature.  
After washes in PBS, coverslips were mounted in 90% glycerol/OPDA and 
sealed with nail polish.  Imaging was performed using an Axiovert 200M 
microscope from Zeiss (Germany) and imaging software from Intelligent Imaging 
Innovations (Denver, CO).  To determine phospho-MLC2 association with stress 
fibers, five representative images for each experimental condition were masked 
for rhodamine-phalloidin intensity and the mean intensity of phospho-MLC2 was 
measured on this mask.   
 
In vitro ubiquitination assay 
The in vitro ubiquitination assay was adapted from (Wang et al., 2006).  
COS-7 cells were transfected with Flag-Smurf1 constructs and anti-FLAG 
immunoprecipitation was done as described above.  The immunopurified Flag-
Smurf1 was then incubated with 10 μg ubiquitin, 0.35 μg rabbit E1, and 0.5 μg 
UbcH5c (E2, Boston Biochem) in a reaction buffer containing 50 mM Tris-HCl 
pH=7.5, 10 mM MgCl2, 10 μM DTT, and 4 mM ATP.  The reaction was incubated 
 32
for 15 minutes at room temperature before ending the reaction with 2X SDS-
PAGE loading buffer and boiling for 5 minutes.  The reaction products were then 
analyzed by Western blot for ubiquitinated species. 
 
In vitro wound healing assay 
bEND.3 cells stably expressing pLKO.1 or CCM2 shRNAs were 
transduced with pLL5.0 for expression of GFP.  Cells were grown in 24-well 
dishes to a monolayer.  Using a P200 pipet tip, a wound across the cell 
monolayer was made across the center of the well.  The cells were then washed 
once with growth medium and incubated at 37º in the BD Pathway High Content 
Imager.  Wounds were imaged on GFP fluorescence every 15 minutes for 16 
hours on a 10X objective.  Percent wound healing was determined as the area of 
the wound remaining after 16 hours divided by the initial area of the wound 
(ImageJ).   
 
Real-time RT-PCR 
Twenty-four hours after the final infection of bEND.3 cells or twenty-four 
hours following puromycin selection, total RNA was isolated using the RNeasy 
Mini Kit (Qiagen) according to the manufacturer’s directions.  From this 
preparation, 3 ug of RNA was used for the RT reaction using High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems).  The RT-PCR assay used 
5 μL of the cDNA reaction combined with 15 μL of 2X Universal Master Mix 
(Applied Biosystems).  The Mus musculus CCM2 Taqman probe 
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(Mm00524581_m1) and Mus musculus beta-actin Taqman probe were 
purchased from Applied Biosystems.  Data were collected on the Applied 
Biosystems 7500 Fast System.  Samples were run in triplicate and standardized 
to beta-actin.   
 
GST-pulldown assay 
GST-Smurf1 C699A was produced exactly as described in (Wang et al., 
2006).  His-CCM2 and His-MEKK3 were purified as described previously (Uhlik 
et al., 2003).  GST-pulldown experiments were done as described in (Nakamura 
et al., 2006). 
 
In vitro tube formation assay 
In a 24 well plate, 350 uL of growth factor-reduced Matrigel (BD 
Biosciences) was polymerized at 37º for 30 minutes.  After polymerization, 1.69 x 
105 cells/well were placed on top of the Matrigel and incubated at 37º for 16 
hours. 
 
HUVEC Permeability Assay 
For permeability assays, 12-mm, 0.4-μm pore Transwells (Corning) were 
coated in Matrigel (BD Biosciences; 1:100 dilution in PBS) for 1 hour.  During this 
time, HUVECs were trypsinized and 5 x 105 cells per condition were 
resuspended in 100 μL MEF nucleofector solution 2 (Amaxa).  To the suspension, 
10 μL of either 20μM siGENOME non-targeting siRNA #2 or CCM2 ON-
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TARGETplus SMARTpool siRNA (Dharmacon) was added.  The suspension was 
electorporated using program M-003 on the Nucleofector Device (Amaxa).  The 
cells were removed from the cuvette, added to 900 μL of growth medium, and 
allowed to recover at 37ºC for 10 minutes.  The cell suspension was then split 
between two Matrigel-coated Transwells; 500 μL of cells were plated in the upper 
chamber with 1.5 mL of growth medium in the lower chamber.  The growth 
medium was changed after 24 hours.  Forty-eight hours post-electroporation, the 
medium from both chambers was removed and replaced with serum- and growth 
factor-free EBM-2.  FITC-dextran (40 kD molecular weight; Invitrogen) was 
added to the upper chamber at a final concentration of 0.625 mg/mL.  As a 
control to induce permeability, EGTA at a final concentration of 4 mM was added 
to one set of control cells to disrupt the Ca2+-dependent cell-cell adhesion 
(Wittchen et al., 2005).  Every 15 minutes for 1.5 hours, 50 μL aliquots were 
removed from the lower chamber, and FITC intensity was measured using a 
PHERAstar microplate reader (BMG Labtech).  Relative fluorescence units 
(RFU) were plotted against time and reported as the average change in RFU per 
minute between duplicate Transwells.   
III.  CCM1 and CCM2 are binding partners; implications for a common 
signaling pathway in CCM 
Introduction 
 Three genes have been identified in the autosomal dominant form of 
cerebral cavernous malformations: CCM1, CCM2, and CCM3 (Bergametti et al., 
2005; Denier et al., 2004; Laberge-le Couteulx et al., 1999; Liquori et al., 2003; 
Sahoo et al., 1999).  The cellular functions of the CCM1, CCM2, and CCM3 
proteins are largely uncharacterized, although CCM1 and CCM2 have both been 
implicated in cell signaling processes by the proteins that they bind.  CCM1 binds 
the GTPase Rap1A and the integrin adaptor ICAP1 suggesting a role for CCM1 
in integrin mediated adhesion and signaling (Serebriiskii et al., 1997; Zawistowski 
et al., 2002).  The mouse homolog of CCM2 was characterized as Osmosensing 
Scaffold for MEKK3 (OSM).  OSM binds Rac1, MEKK3, and MKK3 to activate 
p38 in response to osmotic stress (Uhlik et al., 2003).  CCM3 binds a Ste20-like 
kinase and is associated with activation of Erk signaling (Ma et al., 2007).  
However, the molecular mechanism of how loss of CCM1, CCM2, or CCM3 
leads to CCM is not known.   
CCM1, 2, and 3 are linked genetically and phenotypically, suggesting a 
common signaling pathway associated with loss of expression of any one of 
these proteins.  However, such a pathway has not been found.  The proteins 
encoded by these genes lack identifiable catalytic domains, but do contain 
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protein interaction domains.  CCM1 contains a C-terminal FERM domain and 
multiple ankyrin repeats.  CCM2 contains a PTB domain in its N-terminus.  
Mutations in CCM genes are mostly frameshift or nonsense mutations.  
Therefore, mutations in CCM1, CCM2, or CCM3 could lead to truncated proteins 
or loss of protein expression leading to loss of protein complex formation and 
impaired cell signaling.   
 In this study, we show that CCM1 and CCM2 are binding partners.  The 
CCM2 PTB domain is necessary for a canonical interaction with NPxY motifs 
within CCM1.  We provide evidence of co-immunoprecipitation and fluorescence 
resonance energy transfer (FRET) between CCM1 and CCM2, implicating a 
common genetic and molecular pathway in CCM pathogenesis.   
 The data presented in this chapter was done in collaboration with Drs. Jon 
Zawistowski and Mark Uhlik and was published in Human Molecular Genetics in 
2005 (Zawistowski et al., 2005).   
 
Results 
CCM2+/- cells have perturbed MAPK activation in response to hyperosmotic 
shock 
CCM2 is an osmosensing scaffold for MEKK3-mediated p38 MAPK 
phosphorylation (Uhlik et al., 2003).  We therefore assessed the role of 
endogenous CCM2 protein in activation of sorbitol-induced p38 signaling.  We 
isolated mouse embryonic fibroblasts (MEFs) heterozygous for a gene trap 
insertion in the mouse CCM2 gene.  This gene trap cell line (Bay Genomics 
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RRG051) has a LacZ insertion in exon 6 of CCM2 which is predicted to be a loss 
of function mutation (Plummer et al., 2006).  Heterozygous MEFs were used for 
these experiments because they are the genotypic equivalent of familial CCM 
patients.  We first verified that there was reduced CCM2 protein in heterozygous 
MEFs by western blot with CCM2 antibody (Figure 3.1A).  Cells heterozygous for 
the CCM2 mutation had significantly less activated p38 MAPK in response to a 
sorbitol time course as assessed by p38 Thr180/Tyr182 phosphorylation (Figure 
3.1A-B).  This decrease of p38 phosphorylation was restored in experiments 
where exogenous FLAG-CCM2 was transfected into CCM2 +/- MEFs (CCM2 
add-back, Figure 3.1B), demonstrating that the effect was specific to the 
reduction of CCM2.  These results are consistent with previous work implicating 
CCM2 in this signaling pathway (Uhlik et al., 2003).  
 
CCM1 associates with the CCM2/MEKK3 protein complex 
CCM2 acts as a scaffold for MEKK3-mediated p38 MAPK phosphorylation 
following sorbitol stimulation (Uhlik et al., 2003), but the role of CCM1 in this 
pathway is not known.  To determine whether CCM1 is a member of the 
CCM2/MEKK3 scaffold complex, we expressed epitope-tagged CCM1, CCM2 
and MEKK3, and examined associating proteins by immunoprecipitation with 
anti-CCM2 antibody.  All three molecules were detected in the complex (Figure 
3.2A).   
We hypothesized that the presence of CCM1 in the CCM2/MEKK3 
signaling complex may represent an interaction between CCM1 and CCM2.  To 
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examine the potential for the CCM1 and CCM2 to associate, we performed CFP-
YFP-FRET analysis in live COS-7 cells.  Cells expressing YFP-CCM1 and CFP-
CCM2 yield a FRETNC value of 7.43 x 10-5 (s.e.m. = 1.29 x 10-5) while control 
cells expressing YFP and CFP-CCM2 yield a FRETNC value of 0.35 x 10-5  
(s.e.m. = 0.11 x 10-5 ) (Table 3.1).  Visualization of the corrected FRET value 
revealed a diffuse interaction signal throughout the cytoplasm (Figure 3.2B).   
 We then determined if an osmotic stimulus would affect CCM1/CCM2 
association.  Cells expressing YFP-CCM1 and CFP-CCM2 treated with sorbitol 
displayed a two-fold increase in the FRETNC value over non-treated cells (Table 
3.1).  Localization of CCM1-CCM2 complexes shifted from diffusely cytoplasmic 
to the cell periphery as a consequence of sorbitol stimulation as revealed by 
visualization of the corrected FRET signal (Figure 3.2B).  Re-localization and 
interaction of CCM1 and CCM2 may reflect a functional role for these proteins at 
the plasma membrane. 
 To confirm the interaction of epitope-tagged CCM1/2, we performed co-
immunoprecipitation experiments with endogenous protein.  Endogenous CCM1 
was efficiently co-immunoprecipitated with CCM2 from MEF lysates (Figure 
3.3A).  Therefore, we conclude that CCM1 and CCM2 are binding partners in 
vivo.   
 
A functional CCM2 PTB domain is necessary for interaction with CCM1 
CCM2 contains a PTB domain that is most similar to the ICAP1 PTB 
domain, which binds CCM1 (Chang et al., 1997; Uhlik et al., 2005).  Therefore, 
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we hypothesized the CCM1/CCM2 association was occurring through a 
canonical NPxY/PTB domain interaction.  The CCM2 PTB domain is most similar 
to the Dab-like PTB domains (Uhlik et al., 2005).  Based on the structure and 
binding sites of these domains, we engineered a mutation into CCM2 PTB 
binding pocket that would be predicted to loose association with NPxY motifs.  
Point mutation of the corresponding residue in CCM2 (F217A) completely 
abrogated the ability of FLAG-CCM1 to co-immunoprecipitate with FLAG-CCM2 
(Figure 3.3B), suggesting that PTB domain integrity is critical for the CCM1/2 
interaction.   
We confirmed the effect of the CCM2 F217A mutation on the CCM1/2 
interaction using FRET.  Consistent with co-immunoprecipitation, COS-7 cells co-
expressing YFP-CCM1 and CFP-CCM2 F217A had reduced FRET values 
(FRETNC= 1.355 X 10-5, s.e.m = 0.355 X 10-5) when compared to the FRET 
value for the wild type CCM1/2 proteins (FRETNC = 7.43 x 10-5, s.e.m. = 1.29 x 
10-5) (Table 3.1).  We observed a similar loss of FRET following sorbitol 
stimulation (CCM2-F217A FRETNC = 2.29 x 10-5, s.e.m. =  0.307 x 10-5 ; WT 
FRETNC = 15.77 x 10-5 , s.e.m. =  3.13 x 10-5) (Table 3.1).   
Germline mutations in the CCM1 and CCM2 genes have been exclusively 
nonsense, frameshift and splicing mutations predicted to prematurely truncate 
the message.  However, a missense mutation has recently been identified in one 
CCM2 kindred, CCM2 L198R (Denier et al., 2004).  This mutation occurs within 
the CCM2 PTB domain, which we have found to be necessary for interaction with 
CCM1.  Similar to the CCM2 F217A mutant, the CCM2 F217A mutant was not 
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capable of association with CCM1 as determined by co-immunoprecipitation 
(Figure 3.3B).  Loss of association of CCM1 with the patient mutation CCM2 
L198R suggests that the CCM1-CCM2 interaction may be relevant in CCM 
pathogenesis.   
 
CCM1/CCM2 interaction is not dependent on the same CCM1 NPxY sequence 
critical for ICAP1 interaction 
 Previous work has shown that ICAP1, another PTB domain-containing 
protein, associates with CCM1 through an ICAP1 PTB domain – CCM1 NPxY 
motif interaction (Zawistowski et al., 2002).  CCM1 contains 3 NPxY motifs.  
Therefore, we wanted to determine if CCM2 and ICAP1 were binding to the same 
site on CCM1, or if they could both associate with CCM1 at the same time.  We 
tested this hypothesis by co-immunoprecipitation and found that mutagenesis of 
the critical asparagine (N192A) residue in the CCM1 NPxY motif critical for 
ICAP1 binding did not disrupt the CCM1/2 association (Figure 3.3B).  FRET 
experiments found that CCM1-N192A and CCM2 interactions were diminished 
relative to wildtype CCM1 and CCM2, but interaction was not completely 
abolished (Table 3.1).  The FRET data indicate that the N192A CCM1 mutation 
has a slight effect on CCM1/2 binding, while in the context of co-
immunoprecipitation, it does not perturb the interaction.  This data suggests that 
CCM2 could bind to additional NPXY motifs on CCM1.  To examine if CCM1, 
CCM2, and ICAP1 are able to associate in a ternary complex, we performed a 
CCM1/2 co-immunoprecipitation assay in the presence of increasing amounts of 
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ICAP1.  ICAP1 overexpression did not prevent CCM1 from associating with 
CCM2; instead, all three molecules were present in the complex precipitated with 
the CCM2 antibody (Figure 3.5A).  This suggests that ICAP1 and CCM2 do not 
bind to the same CCM1 binding site and ICAP1, CCM2, and CCM1 can 
associate as a protein complex.   
 
CCM1 contains a functional nuclear localization sequence 
 The interaction of CCM1/2 prompted us to compare the subcellular 
localization of CCM1 with CCM2.  Endogenous CCM2 localizes to actin-rich 
membrane ruffles (Uhlik et al., 2003).  In contrast, we observed a whole cell 
distribution for YFP-CCM1 in COS-7 cells.  We hypothesized that the nuclear 
localization of the CCM1 molecule may be due to a nuclear localization sequence 
(NLS).  Examination of the primary sequence of CCM1 identified a putative NLS 
using the PSORT II program (EXPASY).  A “pat4” four-residue pattern, similar to 
the NLS of the SV40 large T antigen, was predicted at residues 46, 47 and 48 in 
the unique N-terminal region of CCM1 (corresponding to 46-KKKRKK-51).  In 
addition, a “pat4” sequence was detected at residue 569 within the FERM 
domain of CCM1 (corresponding to KKHK). 
The putative N-terminal NLS in CCM1 was changed by site-directed 
mutagenesis from the wild-type KKKRKK to KKAAKK (NLS mutant 1), and also 
to a more severe mutation of KAAAAK (NLS mutant 2).  The resulting constructs 
were transfected into COS-7 cells and assessed for nuclear localization (Figure 
3.4B).  The percentage of cells displaying nuclear localization for FLAG-CCM1 
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NLS mutant 1 was reduced to ~ 40% from the ~ 90% of wild-type FLAG-CCM1 
cells displaying nuclear localization, while nuclear localization for the more 
severe FLAG-CCM1 NLS mutant 2 was reduced to ~ 10% of the cells (Figure 
3.4C).  These data suggest that the putative N-terminal NLS in CCM1 is 
functional, and suggest that CCM1 may have nuclear-cytoplasmic shuttling 
capability.   
 
CCM1 localization is influenced by association with CCM2 
In addition to contributions of the CCM1 NLS to CCM1 subcellular 
localization, we hypothesized that association with CCM2 could influence CCM1 
subcellular localization.  In COS-7 cells, CCM1 exhibits whole cell localization, 
while CCM2 exhibits exclusively cytoplasmic localization.  In cells co-expressing 
YFP-CCM1 and CFP-CCM2, YFP-CCM1 nuclear localization is lost and 
becomes exclusively cytoplasmic (Figure 3.4A).  This suggests that CCM2 is 
capable of interacting with and sequestering CCM1 in the cytoplasm.  To see if 
the cytoplasmic sequestration of CCM1 by CCM2 was dependent on the PTB 
domain integrity of CCM2, we analyzed the effect of the CCM2-F217A mutant on 
CCM1 localization.  In COS-7 cells expressing YFP-CCM1 and PTB-mutant 
CFP-CCM2 F217A, CCM2 fails to interact with and sequester CCM1 and nuclear 
localization of YFP-CCM1 is restored (Figure 3.4A).  These data are consistent 
with our co-immunoprecipitation results and provide support that the cerebral 
cavernous malformations gene products interact in a PTB domain-dependent 
manner.  These data are also consistent with our CCM1 NLS mutagenesis 
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experiments suggesting a nuclear-cytoplasmic shuttling role for CCM1.  We 
conclude that CCM1 can act as a nuclear-cytoplasmic shuttling protein and this 
shuttling of CCM1 can be regulated by CCM2. 
 
ICAP1 influences the subcellular localization of CCM1 
We have demonstrated that CCM2 is capable of influencing the 
localization of CCM1.  ICAP1, which also binds CCM1, may similarly influence 
CCM1 localization.  When expressed alone, CFP-ICAP1 exhibits predominantly 
nuclear localization.  When co-expressed with CFP-ICAP1, YFP-CCM1 
localization shifts from total-cell to exclusively nuclear (Figure 3.5B).  Thus, 
through PTB-domain interactions, ICAP1 and CCM2 are capable of influencing 
the localization (and presumably function) of CCM1.   
 
Discussion 
CCM1 and CCM2 have been implicated in the disease cerebral cavernous 
malformations.  Although mutation of these genes leads to the same disorder, 
there has been insufficient data to understand the mechanism of the 
pathogenesis of CCM.  In this work, we provide evidence that CCM1 and CCM2 
are binding partners, placing them in the same molecular pathway.  This 
interaction is abrogated by a patient mutation in CCM2 (CCM2 L198R) 
suggesting that loss of the CCM1/2 association contributes to the development of 
the abnormal vessels associated with CCM lesions. 
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The characterization of CCM2 as Osmosensing Scaffold for MEKK3 
(OSM) has shed new light on the potential signaling mechanisms that are 
impacted by loss of CCM2 expression.  OSM was found to coordinate osmotic 
stress-induced p38 activation via Rac1, MEKK3, and MKK3.  Indeed, MEKK3 
and p38 knockout mice have shown that these signaling pathways are necessary 
for vascular development and integrity (Adams et al., 2000; Deng et al., 2007; 
Yang et al., 2000).  In this work we have shown that CCM2 heterozygous MEFs 
are defective in their ability to activate p38 in response to osmotic stress.  
Importantly, exogenous expression of CCM2 led to a complete recovery of this 
phenotype.  Further, in this work we demonstrated that CCM1 can associate with 
the CCM2-MEKK3 protein complex, suggesting a role for CCM1 in MEKK3 
mediated signaling pathways.  Impaired p38 activation may influence 
downstream p38-specific transcriptional activation involved in the maturation of 
new vessels and for the maintenance of the existing vessel architecture.  
Therefore the loss of p38 activation may ultimately contribute to the formation of 
the misshapen vascular beds of the cerebral cavernous malformation.   
Until now, the localization of CCM1 had not been examined.  Our 
demonstration of CCM1 as a nuclear-cytoplasmic shuttling protein opens a new 
avenue of study of CCM1 function and regulation.  We also demonstrate that the 
CCM1 binding partners ICAP1 and CCM2 play a role in the localization of CCM1.  
ICAP1 appears to recruit CCM1 to the nucleus, while CCM2 sequesters CCM1 in 
the cytoplasm.  ICAP1 and CCM2 both utilize their PTB domains in their 
interactions with the CCM1 NPxY motifs.  The relative abundance of ICAP1 and 
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CCM2 may dictate the cellular localization of CCM1, or there may be a more 
complex signaling event associated with changes in CCM1 localization.  These 
CCM1-ICAP1 and CCM1-CCM2 complexes clearly warrant further study to 
determine the nuclear and cytoplasmic roles of CCM1.   
ICAP1 is known to regulate integrin-mediated signaling events.  Activation 
of β1 integrins has been shown to recruit ICAP1 to the cytoplasm where it acts as 
an adaptor protein.  ICAP1 is also capable of redistributing to the nucleus after 
integrin engagement.  Therefore, the shuttling of ICAP1-CCM1 complex could be 
regulated by integrin signaling.  In the cytoplasm, CCM1 could associate with 
CCM2 to control MAPK activation in response to integrin-mediated signaling.  In 
this way a CCM1-CCM2 complex would be necessary to bridge signaling 
between integrins and MAPK pathways.  It would then be reasonable to believe 
that loss of expression of CCM1 or CCM2, as is predicted in CCM patients, 
would lead to abhorrent integrin-mediated signaling.  Indeed, endothelial cells in 
sections of CCM lesions appear to have loss of cell-to-cell contact (Clatterbuck et 
al., 2001), suggesting loss of adhesion.   
In this work, we demonstrate that the genetically and phenotypically linked 
CCM1 and CCM2 proteins exist as a protein complex.  We also show that CCM1 
is a nuclear-cytoplasmic shuttling protein, suggesting multifaceted regulation of 
CCM1 function.  We further show that CCM1-CCM2 localization is influenced by 
osmotic stress, which argues that the CCM complex is dynamic. Assaying the 
function and regulation of the CCM1-CCM2 complex will provide further insight 
into the molecular mechanisms of CCM pathogenesis. 
 46
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1:  MEFs heterozygous for a CCM2 gene trap allele have impaired p38 
activation upon hyperosmotic stress. (A) Western blotting with anti-CCM2 
antibody confirms reduction of CCM2 protein in CCM2+/– MEFs (top panel).  Erk 
1/2 was used as a loading control.  Wild-type or CCM2+/– MEFs were serum-
starved and treated for the indicated times with 0.2 M sorbitol or 15 min with 10 
mg ml–1 anisomycin as a positive control for p38 activation (+). Lysates were 
subjected to western blotting with anti-p38 antibody and with anti-phospho 
(Thr180/Tyr182) p38 antibody. (B) Quantification of impaired p38 activation of 
CCM2+/– MEFs and rescue by add-back of CCM2. Fold p38 activation was 
calculated as described in Materials and Methods.   Results are representative of 
three independent experiments. Error bars represent standard error of the mean. 
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Figure 3.2:  CCM1 associates with CCM2. (A) CCM1 is identified in a ternary 
complex with CCM2 and MEKK3. 293T cells were transfected with the indicated 
constructs, immunoprecipitated with anti-CCM2 antibody and subjected to 
western blotting with the indicated antibodies. In addition to HA-MEKK3 and 
FLAG-CCM1 singly co-immunoprecipitating with FLAG-CCM2, a FLAG-
CCM1/FLAG-CCM2/HA-MEKK3 ternary complex is detected. Approximate 
molecular weights are FLAG-CCM1: 85 kDa and FLAG-CCM2: 60 kDa. (B) 
CCM1/CCM2 interact in live cells and this interaction is enhanced upon 
hyperosmotic stress. COS-7 cells transfected with CFP-CCM2 and YFP-CCM1 
were visualized at room temperature and analyzed by FRET. CFP fluorescence, 
YFP fluorescence and corrected FRET (FRETC) were examined for non-treated 
cells (top) and cells were treated with 0.2 M sorbitol for 5 min (bottom). Non-
treated cells yield a diffuse FRETC signal throughout the cytoplasm. Cells treated 
with sorbitol display a re-distribution of CFP-CCM2 and YFP-CCM1 to the cell 
periphery (arrows) and an enhanced FRETC interaction signal at these sites. 
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Donor 
construct 
Acceptor 
construct 
Treatment FRETNC/(CFPxYFP) Standard 
error 
CFP-CCM2 YFP NT 0.35x10–5 0.11x10–5 
CFP-CCM2 YFP-CCM1 NT 7.43x10–5 1.29x10–5 
CFP-CCM2 YFP-CCM1 0.2M 
sorbitol 
15.77x10–5 3.13x10–5 
CFP-CCM2 
F217A 
YFP-CCM1 NT 1.36x10–5 0.36x10–5 
CFP-CCM2 
F217A 
YFP-CCM1 0.2M 
sorbitol 
2.29x10–5 0.31x10–5 
CFP-CCM2 YFP-CCM1 
N192A 
NT 3.95x10–5 0.78x10–5 
CFP-CCM2 YFP-CCM1 
N192A 
0.2M 
sorbitol 
10.28x10–5 1.48x10–5 
 
 
 
 
 
 
Table 3.1. FRET values for CCM1/2 interactions.  COS-7 cells were treated for 5 
min with 0.2 M sorbitol and compared with FRET interaction values of non-
treated (NT) cells. Multiple cells were visualized to obtain normalized 
FRETNC/(CFPxYFP) values (n=10 CFP-CCM2/YFP, n=10 CFP-CCM2/YFP-
CCM1, n=10 CFP-CCM2 F217A/YFP-CCM1 and n=7 CFP-CCM2/YFP-CCM1 
N192A). 
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Figure 3.3:  The CCM1/2 interaction is dependent on the CCM2 PTB domain. (A) 
Endogenous CCM1 co-immunoprecipitates with endogenous CCM2. Following 
immunoprecipitation of MEF lysate with anti-CCM2 and western blotting with anti-
CCM1 antibody, CCM1 is detected as a species migrating near the predicted 
molecular weight of 83 kDa.  100 µg of 293T cell lysate transfected with FLAG-
CCM1 was utilized as a size control for endogenous CCM1. (B) Engineered and 
CCM2 patient PTB domain mutations abrogate the CCM1/2 interaction. FLAG-
CCM1 and FLAG-CCM2 with the indicated mutations were expressed in 293T 
cells, and complexes were immunoprecipitated with anti-CCM2 antibody followed 
by western blotting with anti-FLAG antibody. The engineered CCM2 PTB domain 
mutation (CCM2-F217A) and a CCM2 patient PTB domain mutation (CCM2-
L198R) completely prevent FLAG-CCM1 from being co-immunoprecipitated with 
FLAG-CCM2, whereas NPxY mutation N192A in FLAG-CCM1 does not perturb 
the interaction.  
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Figure 3.4:  CCM1 subcellular localization is influenced by CCM2 and by a CCM1 
NLS. (A) The CCM2 PTB domain regulates CCM1 localization.  COS-7 cells 
were transfected with CFP-CCM2 or CFP-CCM2 F217A with YFP-CCM1 and 
fluorescence was examined in live cells at room temperature. YFP-CCM1 
fluorescence is distributed throughout the cell (closed arrowhead), whereas CFP-
CCM2 fluorescence is predominantly cytoplasmic (open arrowhead). In cells co-
expressing YFP-CCM1 and CFP-CCM2 (arrow), CCM2 is capable of interacting 
with and sequestering CCM1 in the cytoplasm (top panels). This sequestration 
phenotype is lost in cells co-expressing PTB-mutant CFP-CCM2 F217A and 
YFP-CCM1, as YFP-CCM1 exhibits wild-type, whole-cell fluorescence (bottom 
panels). (B) CCM1 possesses a functional NLS. Wild-type FLAG-CCM1 in COS-
7 cells localizes to both the nucleus and the cytoplasm, whereas FLAG-CCM1 
NLS mutant 2 (KKRKKK KAAAAK) is predominantly cytoplasmic in the majority 
of cells as revealed by anti-FLAG immunofluorescence. Magnification: 40x. (C) 
Percentage of cells exhibiting FLAG-CCM1 nuclear localization following NLS 
mutagenesis. n=150 
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Figure 3.5:  ICAP1 associates with CCM1 and CCM2 and sequesters CCM1 in 
the nucleus. (A) ICAP1 does not compete with CCM2 for binding to CCM1, but is 
a member of a ternary complex with CCM1 and CCM2. 293T cells were 
transiently transfected with the indicated constructs. Cell extracts were analyzed 
by immunoprecipitation using a polyclonal antibody to CCM2 followed by western 
blotting with anti-FLAG antibody. (B) ICAP1 sequesters CCM1 in the nucleus. 
COS-7 cells were transfected with YFP-CCM1 alone and co-transfected with 
CFP-ICAP1. Live COS-7 cells transfected with YFP-CCM1 alone exhibit whole-
cell fluorescence, whereas YFP-CCM1 is sequestered in the nucleus when co-
expressed with CFP-ICAP1. (C) Molecular model for CCM protein function. 
CCM1 can act as nuclear-cytoplasmic shuttling protein.  In the presence of 
ICAP1, CCM1 is predominantly nuclear.  In the presence of CCM2, CCM1 is 
predominantly cytoplasmic, where it can associate with the MEKK3 signaling 
module. 
Nucleus 
IV.  CCM2 regulates aortic arch morphogenesis in Danio rerio 
Introduction 
Cerebral cavernous malformations (CCMs) are lesions of the central 
nervous system composed of clusters of dilated thin-walled blood vessels.  
Patients with this disorder are at high risk of seizures and stroke due to potential 
hemorrhage of the lesion.  To date, three genes have been linked to familial 
CCM:  CCM1 (KRIT1), CCM2 (OSM), and CCM3 (PDCD10).  The physiological 
and cell signaling roles of these proteins are not fully characterized although all 
appear to exist in a protein complex (Hilder et al., 2007).  Knock-out mice for 
CCM1 and CCM2 have been generated; however, using the mouse as a model 
to study the physiological function of these proteins has proven to be problematic 
due to early embryonic lethality (Plummer et al., 2006; Whitehead et al., 2004).  
We have utilized zebrafish (Danio rerio) as a model organism to better 
understand the roles of these proteins in embryonic development and in the 
pathogenesis of CCM.  Using translational blocking morpholinos, we can 
successfully knock-down CCM2 expression.  CCM2 morpholino-treated embryos 
have decreased blood flow at 24 and 48 hours post fertilization (hpf) due to a 
restriction in the first aortic arch.  Zebrafish embryos lacking CCM2 expression 
also show pronounced defects in the development of the optic tectum and 
abnormal closure of the cranial neural tube.  We conclude that Danio rerio is a 
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viable model organism to examine the physiological role of CCM2 in vertebrate 
development.  We also show that loss of CCM2 in zebrafish leads to 
developmental vascular abnormalities similar to those seen in CCM1 knockout 
mice, suggesting a common molecular pathway for CCM protein function. 
This work was done in collaboration with Drs. Mike Malone and Elwood 
Linney.  Blood flow analysis was published in BMC Biotechnology (Malone et al., 
2007).  
 
Results 
The model organism Danio rerio has a CCM2 homolog 
Danio rerio is a prominent animal model for vertebrate development.  This 
species has been utilized for decades because of its optical clarity, genomic 
amenability, and most importantly, rapid and external gestation.  Lack of CCM2 
expression in the mouse leads to embryonic lethality around E9.5 (Plummer et 
al., 2006).  Therefore we considered using Danio rerio as an alternative model 
vertebrate organism to examine CCM2 function in vivo.   
To determine if CCM2 had a homolog in Danio rerio, we used the program 
BLAST to compare human CCM2 sequence (Accession NP_113631) to genes of 
the Danio rerio genome.  A zebrafish CCM2 homolog was identified (Accession 
NP_001002315).  These two proteins were found to be 75% identical based on 
their amino acid sequence (Figure 4.1).  Similar to human CCM2, the zebrafish 
CCM2 protein contains a PTB domain in the amino-terminus.  Importantly, 
residues we had previously identified in human CCM2 as crucial for PTB domain 
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integrity, F217 and L198, are conserved in the zebrafish CCM2 protein 
(Zawistowski et al., 2005).   
 
CCM2-specific morpholinos knock down CCM2 expression 
CCM2-specific morpholinos were designed near the translational start site 
on Danio rerio CCM2 RNA.  CCM2 morpholino #1 targeted the mRNA sequence 
directly adjacent to the start-site ATG.  CCM2 morpholino #2 overlapped the 
start-site ATG and initial 5’ coding sequence (Figure 4.2).  These two 
independent CCM2 morpholinos were capable of knocking-down CCM2 
expression.  Western blots of embryo lysates demonstrated a clear inhibition of 
CCM2 expression both at 24 and 48 hours post-fertilization (hpf, Figure 4.2).   
 
CCM2 knockdown leads to decreased embryonic blood flow 
 In order to determine the role of CCM2 in vertebrate development, we 
injected CCM2 morpholinos into zebrafish embryos.  Wild-type embryos at the 1- 
to 4- cell stage were injected with CCM2 morpholinos or left uninjected as a 
control.  Embryos were monitored at 24 and 48 hours post-fertilization for 
phenotypes.  Embryos injected with CCM2 morpholinos (CCM2 morphant 
embryos) developed normally until about 24 hpf.  CCM2 morphant somite 
development was normal in both the number and morphology of somites.  The 
yolk sac, tail, and body axis appeared normal.  However, beyond 24 hpf 
differences became more clear between uninjected and CCM2 morphant 
embryos.  CCM2 morphant embryos displayed loss of pigmentation and flat 
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heads compared to control embryos (Figure 4.3).  In addition to these 
developmental defects, the most pronounced defect we observed was loss of 
blood circulation. 
 In the developing zebrafish embryo, blood flow initiates around 24 hpf, 
when the heart beat initiates.  During the first few hours of embryonic blood flow, 
blood circulates from the yolk ball to the heart and through the dorsal aorta and 
caudal vein (Kimmel et al., 1995).  In our CCM2 morphant embryos, blood flow 
appeared to be restricted, with an abundance of blood cells accumulated in the 
yolk sac but not distributed throughout the embryo.  We quantified this 
erythrocyte flux and determined that loss of CCM2 expression led to a dramatic 
loss of blood flow throughout the embryo (Figure 4.4).  Loss of embryonic blood 
flow was not due to changed diameter of the intersomitic vessels or dorsal aorta 
(Figure 4.4).  These defects were observed with two independent CCM2 
morpholinos, implying that loss of embryonic blood flow was specific to CCM2 
knockdown.   
 
Morphant embryos have normal vascular patterning and bulbus arteriosus 
development 
 To determine the reason for loss of blood flow in CCM2 morphant 
embryos, we examined the vascular patterning and heart development in these 
embryos.  Using time-lapse microscopy, control and CCM2 morphant embryos 
were monitored for blood flow.  These movies of embryonic blood flow were then 
used to determine where blood had distributed throughout the embryo.  We 
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termed this technique “in silico microangiography”, as it essentially replaces the 
more traditional method of injecting ink or fluorescent dye into the heart and 
examining where the blood is distributed.  Based on these measurements, the 
CCM2 morphants did have proper vascular patterning, with correct growth of the 
dorsal aorta, caudal vein, and intersomitic vessels (Figure 4.5).   
 Another explanation for loss of blood flow was improper heart 
development.  In the zebrafish model, many of the most complex processes in 
heart development occur before 24 hpf.  Fate mapping experiments have 
identified the paths taken by cardiac precursors from pre-gastrulation to adult.  
The cardiac progenitors ingress during gastrulation and migrate to the lateral 
plate mesoderm.  At the cranial midline, they fuse to form the primitive heart tube 
which begins beating around 24 hpf.  The atrial and ventricle chambers develop 
and are easily identifiable by 36 hpf (Stainier et al., 1993).  In the developing 
embryo, the bulbus arteriosus is a component of the teleost heart that is formed 
during the last stages of heart development.  Therefore, the presence of the 
bulbus arteriosus is indicative of proper heart development.  DAF2-DA, a marker 
for the bulbus arteriosus, was recently characterized (Grimes et al., 2006).  In 
order to examine bulbus arteriosus development in our CCM2 morphant 
embryos, we treated live embryos with DAF2-DA.  Both control and CCM2 
morphant embryos had strong DAF2-DA staining, suggesting that heart 
development was predominantly normal (Figure 4.5).  Based on these 
experiments we concluded that neither vascular patterning nor heart 
development was inducing the loss of blood flow in CCM2 morphant embryos. 
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Loss of CCM2 causes malformations of the first aortic arch  
 Careful examination of CCM2 morphant embryos revealed that blood flow 
was being restricted near the outflow tract of the heart.  Blood cells had 
accumulated in the yolk sac; even though the heart was developed and pumping.  
Upon microscopic evaluation of the CCM2 morphant embryos, we discovered a 
restriction in the proximal dorsal aorta, specifically in the aortic arch.  Using in 
silico microangiography, these defects were more clearly seen (Figure 4.6).  
Control embryos had an aortic arch that was a consistent diameter.  CCM2 
morphant embryos displayed a restriction in the aortic arch near the outflow tract 
of the heart that ballooned past the restriction (Figure 4.6).  Based on this data 
we concluded that CCM2 is necessary for morphogenesis of the aortic arch in 
Danio rerio.   
 
CCM2 morphants have developmental defects of the head and trunk 
 Although the loss of blood flow was the most obvious phenotype we 
observed in CCM2 morphant embryos, these embryos had additional defects of 
the head and trunk.  The first of these defects was seen in the region of the 
cranial neural tube.  At 30 hpf, a developmental timepoint past neural tube 
closure, CCM2 morphants had heads that were more flat than uninjected controls 
(Figure 4.3).  In many vertebrate systems, flat head phenotypes are indicative of 
neural tube defects.  Indeed, the neural tube closure in CCM2 morphant embryos 
was not normal.  Microscopic examination of the ventral cranial region of the 
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CCM2 morphant embryo found that the neural tube was closed, but the ventral 
point of closure contained less contact compared to the control embryos (Figure 
4.7).  This could indicate some form of developmental delay, or a true neural tube 
closure defect.   
 CCM2 morphants also lacked development of the optic tectum (Figure 
4.8).  Around 24 hpf, the embryonic brain undergoes segmentation.  One of the 
final regions to undergo segmentation is the midbrain.  The midbrain primordium 
subdivides horizontally to form the dorsal and ventral sections, the optic tectum 
and midbrain tegmentum, respectively.  Upon both microscopic inspection of live 
embryos and embryo sections, CCM2 morphant embryos lacked development of 
the optic tectum.  This data suggests that in addition to the aortic arch defects, 
neural developmental defects are also occurring in CCM2 morphant embryos.   
 
Discussion 
Danio rerio has proven to be a beneficial tool in our understanding of 
vertebrate development.  Many developmental processes that occur in 
mammalian systems are conserved in zebrafish, making this system a cost-
effective alternative to mouse models.  For early embryonic lethalities zebrafish 
are a more desirable model since the embryos develop externally.  Furthermore, 
zebrafish can survive without a functioning cardiovascular system until 48 hpf.  
Since much of the early vasculature forms before 48 hpf, this makes Danio rerio 
ideal for studying vascular abnormalities.  Using translational blocking 
morpholinos to CCM2, we have begun to characterize the developmental defects 
 59
associated with CCM2 loss.  We have found that morpholino knockdown of 
CCM2 leads to decreased embryonic circulation, due in part to constriction of the 
first aortic arch.   
Our observations in zebrafish suggest a common evolutionary role for 
CCM2 in vascular development.  A gene-trap knockout model for CCM2 in mice 
demonstrated that complete loss of CCM2 expression leads to embryonic 
lethality at E9.5 (Plummer et al., 2006).  Mice heterozygous for the CCM2 gene-
trap allele developed CCM lesions, albeit at a low penetrance.  Recently the 
mechanism of this embryonic lethality of the CCM2 gene-trap model was 
characterized and found to be strikingly similar to our zebrafish CCM2 
knockdown model.  At E8.5, mouse embryos null for CCM2 expression had a 
narrow and irregular dorsal aorta which prevented embryonic blood flow 
(Whitehead et al., 2009).  Another recently published work examined CCM2 
morphant embryos (Kleaveland et al., 2009).  In this work, CCM2 morphant 
zebrafish were analyzed for vascular patterning and heart development.  Similar 
to our results, CCM2 morphant zebrafish demonstrated proper vascular 
patterning and blood flow in CCM2 morphant embryos was diminished due to a 
proximal aortic constriction.  Therefore, based on two independent studies in 
zebrafish and mouse model systems, CCM2 is clearly involved in aorta 
morphogeneic processes.   
The zebrafish homologs of CCM1 and CCM2 have been identified in N-
ethyl-N-nitrosourea (ENU) mutagenesis screens for genes necessary for 
cardiovascular development (Chen et al., 1996; Stainier et al., 1996).  CCM1 and 
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CCM2 homologs, santa and valentine respectively, both exhibited large, 
distended hearts by 48 hours post fertilization (hpf, (Mably et al., 2006).  These 
mutants were unable to circulate blood, even though there was a beating heart.  
Further examination of the santa and valentine embryos were found to have a 
myocardial layer of only one cell thick, when the normal embryo should have 2-3 
cell thick layer.  These hearts displayed differentiated cardiac markers but lacked 
endocardial cushions.  As the number of myocytes and number of endocardial 
cells were found to be equal between wild type, santa, and valentine embryos, it 
was hypothesized that santa and valentine were required for the concentric 
growth of the heart.  In this condition, the cells proliferate to the normal cell 
number, but the growth occurs around the perimeter of the heart instead of in 
layers, leading to very large, dilated heart chambers.  In our CCM2 morphant 
embryos, we did observe pericardial edema in a fraction of embryos (data not 
shown); although our measure of heart development, DAF2-DA staining, 
suggested that heart development was predominantly normal.  We believe that 
since the major events in heart development (heart tube formation, looping, 
atrium and ventricle specification) did occur, that these hearts would be DAF2-
DA positive, meaning the loss of concentric growth associated with mutations in 
santa and valentine may not be sufficient to block bulbus arteriosus 
development.   
Our CCM2 morphants also exhibited developmental defects of the optic 
tectum and neural tube.  The expression patterns determined for santa and 
valentine may explain these additional phenotypes (Mably et al., 2006).  By in 
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situ hybridization, at 28 hpf santa and valentine were expressed throughout most 
of the brain, with strong expression in the ventricular zone.  In mice, significant 
neuronal expression of CCM2 has also been observed (Plummer et al., 2006).  
Based on these expression patterns, neural abnormalities would be predicted 
with CCM2 knockdown.  Neural defects have not been characterized in other 
CCM2 animal models, suggesting that this defect could be specific to zebrafish.   
The aortic arch defects observed in CCM2 morphant embryos are 
strikingly similar to defects seen in the CCM1 gene-trap mouse model, 
suggesting a genetic link between CCM1 and CCM2 (Whitehead et al., 2009; 
Whitehead et al., 2004).  Studies have proven a genetic link between CCM1 and 
CCM2 in zebrafish.  Santa and valentine were found to be genetically in the 
same pathway based on treatment of embryos with santa and valentine 
morpholinos in combination (Mably et al., 2006).  Injection of both santa and 
valentine morpholinos led to a dramatic increase in the number of embryos with 
heart defects compared to embryos injected with either santa or valentine 
morpholinos alone, suggesting alteration of a common signaling pathway.  This is 
consistent with our characterization of CCM1 and CCM2 as molecular binding 
partners (Zawistowski et al., 2005).   
How do the morphogenic processes in aortic arch formation relate to 
human CCM?  Of all the animal models generated for the CCM genes, the only 
model to consistently have brain malformations similar to CCM patients was the 
CCM1 +/- Trp53 -/- mouse model (Plummer et al., 2004).  This implies that a 
somatic mutation event leads to endothelial defects and CCM formation post-
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natal.  Although our model does not form brain lesions, it is possible to gain 
information pertinent to CCM from animal models that do not form brain lesions.  
The same signaling pathways involved in morphogenesis of the aortic arch could 
well be involved in maintenance of the vasculature of the brain.  Further study is 
necessary to determine these signaling pathways associated with CCM1, CCM2, 
or CCM3 loss in endothelial cells.   
In this work we characterize a zebrafish model for CCM2.  We show that 
loss of CCM2 expression leads to decreased embryonic blood flow due to aorta 
morphogenic defects.  The phenotypes characterized here confirm the 
importance of CCM2 in vascular development.  As these defects phenocopy 
defects in CCM1-null mice and zebrafish, we provide additional support that 
CCM1 and CCM2 are in a common signaling pathway relevant to CCM 
pathogenesis.   
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Figure 4.1:  The Danio rerio CCM2 homolog.  T-Coffee alignment (EMBL-EBI) of 
the human CCM2 amino acid sequence (Accession NP_113631) and the Danio 
rerio CCM2 amino acid sequence (Accession NP_001002315).  The predicted 
PTB domain of Danio rerio CCM2 is underlined.  The conserved residues that 
have been previously shown to be necessary for PTB domain integrity are 
designated with an asterisk.   
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Figure 4.2:  CCM2 knockdown strategy.  Translational blocking morpholinos were 
designed to the region surrounding the translational start site of CCM2 mRNA.  
The start site ATG is underlined.  Morpholinos were injected into 1 to 4 cell stage 
zebrafish embryos.  After 24 or 48 hours, whole embryo lysate was analyzed for 
CCM2 protein knockdown using a polyclonal CCM2 antibody. 
5’UTR……ATCTAATACAGCGAAAATGAAGAGCATTTGTACGTAGAG
ATGGAGGAGGATGTAAAGAAAGTCAAAAAG……
CCM2 MO #1 CCM2 MO #2
48 hpf24 hpf
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Figure 4.3:  CCM2 morphant phenotype.  Thirty hours post fertilization (hpf), 
embryos were analyzed by light microscopy.  CCM2 morpholino-treated embryos 
displayed a flat head compared to wild type embryos.  Morpholino-treated 
embryos also appear to be hypo-pigmented. Embryos have the proper number 
and size of somites.   
 
 
 
CCM2 MO
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Figure 4.4: CCM2 (OSM) morphants have decreased blood flow in comparison to 
wild type embryos while blood vessel diameter is unaffected.  2-D DIC images 
were obtained from 48 hpf embryos.  Erythrocyte flux and vessel diameter was 
measured using linescan imaging across the dorsal aorta and intersomitic 
vessels. 
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Figure 4.5:  CCM2 morphant embryos have normal vascular patterning and 
bulbus arteriosus development.  A) Top: In silico microangiography was 
performed on wild type and CCM2 morpholino-treated embryos at 48 hpf.  The 
red tracings denote where blood has circulated.  Bottom: In silico 
microangiographs of control and CCM2 morphant zebrafish embryos.  
Arrowheads denote the position of the aorta, the arrows denote the caudal vein, 
and the asterisk denotes the position of the intersomitic vessels.  Note that 
intersomitic vessels are in the proper orientation and make complete dorsal and 
ventral connections. B) Live wild type and CCM2 morpholino treated embryos 
were incubated with DAF2-DA for 4 hours to label the bulbus arteriosus (arrow).  
Note that the bulbus arteriousus is present and in the proper size and shape in 
CCM2 morpholino-treated embryos. 
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B. 
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Figure 4.6:  Aortic arch malformation in CCM2 morphant embryos.  Wild type and 
CCM2 morpholino-treated embryos were analyzed by in silico microangiography 
at 24 hpf.  In morpholino-treated embryos, the aortic arch (boxed) is constricted.  
H = Heart, E = Eye, YB = Yolk ball.   
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Figure 4.7:  CCM2 morpholino-treated embryos have abnormal neural tube 
closure.  Examination of embryos at 30 hpf dorsally revealed atypical neural tube 
closure in morpholino-treated embryos (arrow).   
CCM2 MOWT
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Figure 4.8:  CCM2 morphant embryos do not develop an optic tectum.  Top:  Live 
embryos 30 hpf do not appear to have an optic tectum (tec).  Bottom:  Cross-
sections of 48 hpf embryos confirms lack of tectum developent.   
Paraformaldehyde-fixed embryos were cryosectioned at 6 μm and stained with 
hematoxylin and eosin.   
tec
WT CCM2 MO
30 hpf
48 hpf
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V.  CCM2 acts as a negative regulator of ROCK signaling by promoting 
Smurf1-mediated degradation of RhoA 
Introduction 
We previously characterized a scaffold-like protein named Osmosensing 
Scaffold for MEKK3, (OSM), for its ability to bind actin, localize to Rac-containing 
membrane ruffles, and its obligate requirement for p38 activation in response to 
hyperosmotic stress (Uhlik et al., 2003).  Simultaneously, the gene encoding 
OSM, CCM2, was found to be mutated in the human disease cerebral cavernous 
malformations (Liquori et al., 2003). Cerebral cavernous malformations (CCM) 
are vascular lesions of the central nervous system characterized as clusters of 
dilated, thin-walled blood vessels.  CCM lesions are fragile and prone to vascular 
leakiness and rupture, leading to hemorrhages that cause seizure and stroke 
(Marchuk et al., 2003; Plummer et al., 2005).   
In addition to CCM2, the familial form of CCM has been mapped to 
mutations in 2 other genes, CCM1 and CCM3 (Bergametti et al., 2005; Sahoo et 
al., 1999; Zhang et al., 2000b).  CCM1 encodes KRIT1, a Rap1A effector protein 
that is required for maintenance of endothelial cell junctions (Glading et al., 
2007).   CCM1/KRIT1 contains multiple ankyrin repeats, a carboxy-terminal 
FERM domain, and NPxY motifs which interact with the PTB domain of 
CCM2/OSM (Zawistowski et al., 2005).  The CCM3 gene encodes Programmed 
Cell Death 10 (PDCD10), a gene up-regulated in the human myeloid cell line TF-
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1 upon induction of apoptosis (Bergametti et al., 2005).  Although CCM3 does 
not have any predicted domain structure, it also binds CCM2 (Hilder et al., 2007).  
Based on these data, we have proposed a CCM protein complex that contains 
these proteins.   
Bi-allelic germline and somatic mutations and loss of specific CCM protein 
expression have been seen in endothelial cells of CCM lesions but not interstitial 
cells (Akers et al., 2009; Pagenstecher et al., 2009).  This finding confirms the 
two-hit hypothesis for CCM pathogenesis and also suggests that CCM is a 
disease associated with complete loss of specific CCM gene expression in 
endothelial cells and subsequent endothelial cell dysfunction.  Recently, CCM2 
knockdown endothelial cells were shown to have increased activation of RhoA 
(Whitehead et al., 2009), although the mechanism was not defined.  Herein, we 
demonstrate a molecular mechanism for activation of this pathway.  Through a 
novel CCM2 PTB domain interaction with the Smurf1 HECT domain, we now 
show that CCM2 binds the E3 ligase Smurf1 for the control of RhoA degradation.  
This work was done in collaboration with Dr. Tom Hilder, who provided 
permeability assay data and CCM2 pull-down of endogenous Smurf1. 
 
Results 
CCM2 binds Smurf1 
We have previously demonstrated that MEKK3, a Ste11-like MAP3K that 
regulates the p38 pathway in mammalian cells in response to hyperosmolarity 
(Uhlik et al., 2003), binds to CCM2 and is a component of a larger CCM1-CCM2-
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CCM3 protein complex (Hilder et al., 2007).   MEKK3 is highly homologous to 
MEKK2, and both contain a conserved PY motif that, in MEKK2, has been shown 
to bind the E3 ubiquitin ligase Smurf1 (Yamashita et al., 2005).  Therefore, we 
asked if Smurf1 was found in the CCM protein complex, possibly by binding to 
the PY motif of MEKK3.  Cells stably expressing FLAG-tagged wild type CCM2 
or a CCM2 PTB domain mutant that is unable to bind NPxY motifs in target 
proteins (CCM2-F217A), were used in co-immunoprecipitation assays to define 
endogenous proteins that bind to the CCM protein complex (Hilder et al., 2007).  
Figure 5.1A shows that endogenous Smurf1 co-immunoprecipitated with FLAG-
CCM2 but not CCM2 F217A, indicating that Smurf1 associates with the CCM2 
protein complex in a PTB domain-dependent manner.  
MEKK3 binds CCM2 independent of the CCM2 PTB domain (Hilder et al., 
2007), suggesting that Smurf1 association with the CCM complex may be 
independent of MEKK3.  We utilized a catalytically inactive mutant of Smurf1, 
Smurf1 C699A, to examine these protein-protein interactions, as it is unable to 
ubiquitinate and degrade Smurf1 substrates (Wang et al., 2006).  We expressed 
Smurf1 C699A with MEKK3, CCM2, or MEKK2, a known substrate of Smurf1 
(Yamashita et al., 2005).  Figure 5.1B shows that MEKK2, MEKK3 and CCM2 
are all able to co-immunoprecipitate with Smurf1C699A.   
We used GST-Smurf1 protein purified from bacteria and MEKK3 and 
CCM2 expressed and purified from SF-9 cells to examine if interactions between 
the E3 ligase and MEKK3 and CCM2 are direct.  CCM2 and MEKK3 both directly 
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bind GST-Smurf1 (Figure 5.1C), demonstrating that Smurf1 and CCM2 are 
binding partners both in vivo and in vitro.  
 
CCM2 binds Smurf1 via a PTB domain - HECT domain interaction   
Smurf1 is a member of the NEDD4 family of E3 ligases, which have a 
common domain structure of an amino-terminal C2 domain followed by multiple 
WW domains and a carboxy-terminal HECT domain (Ingham et al., 2004).  
Smurf1 constructs were generated that encoded either the N-terminal moiety of 
Smurf1 (FLAG-Smurf1 ΔHECT containing the C2 and WW domains), or the C-
terminal moiety of Smurf1 (FLAG-Smurf1 HECT encoding only the HECT 
domain).  Co-expression of the Smurf1 moieties with CCM2 indicated that CCM2 
predominantly bound the HECT domain with little binding to the N-terminal 
portion of Smurf1 (Figure 5.2A), indicating that CCM2 was binding specifically to 
the HECT domain.  Consistent with this, the HECT domain of Smurf1 was 
sufficient to bind CCM2 by co-immunoprecipitation.  Smurf1 and Smurf2 are 
highly homologous in their HECT domains (Lin et al., 2000).  Figure 5.2B 
demonstrates that CCM2 binds both Smurf1 and Smurf2, as would be predicted.  
Consistent with the CCM2 pull down of endogenous Smurf1 (Figure 1A), the 
interaction between full length Smurf1 or the Smurf1 HECT domain requires a 
functional CCM2 PTB domain (Figures 5.2C and D).  To our knowledge this is 
the first demonstration of a PTB domain-HECT domain interaction. 
The consensus PTB-binding motif is Asn-Pro-X-Tyr (NPxY), where X is 
any amino acid (Smith et al., 2006).  Examination of the amino acid sequence of 
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the Smurf1 HECT domain identified an NPYY motif (AA 457-460) that is also 
conserved in the Smurf2 HECT domain.  The tyrosine of the NPxY motif is critical 
for interaction of binding partners with many PTB domains (Smith et al., 2006). 
Mutation of Y460 within the Smurf1 NPYY motif to alanine had little effect on 
interaction with CCM2 by co-immunoprecipitation (data not shown).  Engineering 
combinations of mutations involving two mutations within the NPYY motif of 
Smurf1 determined that N457A/Y460A (APYA) had a partial inhibition of 
association, while mutation at residues Y459 and Y460 (NPAA referred to as 
Smurf1 YY-AA below) caused a loss of detectable association with CCM2 
(Figure 5.2E).  These results indicate that CCM2, via its PTB domain, requires 
the NPYY motif within the Smurf1 HECT domain for binding.   
 
CCM2 is not a Smurf1 substrate, nor does it affect Smurf1 catalytic activity   
 Since CCM2 is a Smurf1 binding protein, it was not known if CCM2 was a 
substrate for Smurf1-mediated degradation.  In cells expressing Smurf1 WT, or 
Smurf1 C699A, there was no change in abundance of CCM2 relative to control 
transfected cells, although a loss of known Smurf1 substrates, RhoA and 
MEKK2, was observed (Figure 5.3A).  These results indicate that CCM2 is not a 
substrate for Smurf1-mediated ubiquitination and degradation.  This is consistent 
with what is known about substrate recognition by NEDD4 family E3 ligases.  
Most NEDD4 family members interact with their substrates via their WW domains 
(Ingham et al., 2004).  In most cases, this occurs through a canonical interaction 
of the WW domain with a PY motif within the substrate (Ingham et al., 2005; 
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Ingham et al., 2004).  CCM2 interacts with the Smurf1 HECT domain via its PTB 
domain, and negligibly with the amino-terminal moiety of Smurf1 that contains 
the WW domains.  This is consistent with CCM2 not being a substrate for 
Smurf1.   
The HECT domain catalyzes the ubiquitination of Smurf1 substrates.   
Binding of CCM2 to the Smurf1 HECT domain could therefore regulate the 
catalytic activity of Smurf1.  Expression of CCM2 with Smurf1 neither significantly 
increased nor decreased the catalytic activity of Smurf1 in a Smurf1 
ubiquitination assay (Figure 5.3B).  Furthermore, the Smurf1 YY-AA mutation, 
which cannot bind CCM2, was still catalytically active in a Smurf1 in vitro 
ubiquitination assay (Figure 5.3C), indicating that the CCM2 interaction with the 
NPYY motif of the Smurf1 HECT domain does not affect the catalytic activity of 
Smurf1.   
 
Co-expression of CCM2 and Smurf1 leads to cell rounding    
When expressed in COS-7 cells CCM2 was localized in the cytoplasm 
with enhanced localization at the plasma membrane (Figure 5.4A).  Smurf1 was 
also localized at the cell periphery, a function of the C2 domain of NEDD4 family 
members (Plant et al., 1997).  When co-expressed, Smurf1 and CCM2 co-
localized to the plasma membrane and induced a dramatic rounding of cell 
morphology (Figure 5.4B).  Cell rounding was not observed in cells expressing 
CCM2 or Smurf1 alone, nor in cells expressing CCM2 and Smurf1 C699A 
(Figure 5.4A and D).  The phenotype induced by co-expression of CCM2 and 
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Smurf1 suggested that the CCM2-Smurf1 complex is altering the cytoskeleton 
and adherence of COS-7 cells.  Cells co-expressing CCM2 and Smurf1 YY-AA, 
which cannot bind CCM2, did not show a cell rounding phenotype (Figure 5.4C), 
suggesting a CCM2-Smurf1 complex is required for inducing the rounded 
morphology.   
 
CCM2 localizes Smurf1 by binding the HECT domain   
The C2 domain localizes Smurf1 to the plasma membrane.  Therefore, 
CCM2 binding is not required for membrane localization of Smurf1, but would be 
predicted to localize Smurf1 to CCM2 protein complexes.  As expected, the 
Smurf1 HECT domain, when expressed alone, was not able to localize to the cell 
membrane and remains cytoplasmic because it lacks a C2 domain (Figure 5.4E).  
Expression of CCM2 with the Smurf1 HECT domain resulted in relocalization of 
the Smurf1 HECT domain to the plasma membrane, where it co-localized with 
CCM2 (Figure 5.4E).  Thus, the CCM2 PTB-Smurf1 HECT domain interaction 
localizes Smurf1 to CCM2 complexes primarily at the cell periphery.   
 
CCM2 regulates RhoA degradation   
Smurf1 is an E3 ligase for RhoA, whose degradation could result in the 
morphological changes we observed in cells expressing CCM2 and Smurf1 
(Figure 5.4, (Wang et al., 2003)).  We hypothesized that CCM2 regulates 
Smurf1-mediated degradation of RhoA.  To define the function of CCM2 in brain 
endothelial cells, RNAi was used to knockdown CCM2 expression.  Using a 
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lentivirus-based shRNA system, brain microvascular endothelial cells (bEND.3) 
were infected with either a control vector (pLKO.1) or two independent CCM2 
shRNA vectors.  The bEND.3 cells were analyzed for CCM2 RNA knockdown by 
RT-PCR assay.  Both shRNA constructs were found to be effective at knocking 
down CCM2 RNA by 90% (Figure 5.5C).  Cells expressing shRNA for CCM2 had 
increased levels of RhoA as determined by immunoblotting (Figure 5.5A).  These 
cells did not show a significant increase in RhoA transcription (Figure 5.5D), 
suggesting that the increased RhoA detected was occurring post-
transcriptionally.  Importantly, knockdown of CCM2 did not affect abundance of 
the Smurf1 substrate MEKK2, the Smurf1 interacting protein MEKK3, or the 
GTPase Rac1 (Figure 5.5A).  These findings indicate that loss of CCM2 
expression selectively facilitates degradation of RhoA, but not other Smurf1 
substrates such as MEKK2. 
In order to determine if CCM2 could be facilitating Smurf1-mediated 
degradation of RhoA, we expressed increasing amounts of CCM2 in combination 
with Smurf1 and RhoA (Figure 5.5B).  Cells expressing Smurf1C699A and 
increasing amounts of CCM2 had little effect on RhoA levels.  In contrast, 
increasing amounts of CCM2 in the presence of wild type Smurf1 led to 
significant loss of RhoA protein, consistent with CCM2 regulating Smurf1 
dependent RhoA degradation.  
 
Knockdown of CCM2 in brain microvascular endothelial cells leads to 
dysregulation of the actin cytoskeleton  
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Expression of Smurf1 and CCM2 in COS-7 cells led to increased cell 
rounding (Figure 5.4B), suggesting that the Smurf1-CCM2 complex is involved in 
cytoskeletal regulation.  Furthermore, CCM2 knockdown in bEND.3 cells resulted 
in increased RhoA protein levels, consistent with CCM2 controlling RhoA-
dependent cytoskeletal dynamics.  Figure 5.6 shows that CCM2 knockdown in 
the bEND.3 brain endothelial cells resulted in increased stress fiber formation 
when compared to cells expressing the control vector.  Two different shRNAs for 
CCM2 each gave similar increases in stress fiber formation, demonstrating these 
are likely on-target effects of CCM2 knockdown (Figure 5.7).  Because CCM2 
regulates RhoA abundance and increases stress fiber formation, we examined if 
CCM2 knockdown affected downstream signaling pathways by measuring the 
phosphorylation of MLC2, a substrate for Rho kinase (Amano et al., 1996).  
CCM2 knockdown cells have a significant increase in phospho-MLC2 associated 
with stress fibers compared to control cells. (Figure 5.7).  Treatment of CCM2 
knockdown cells for 24 hours with 10 μM Y-27632, an inhibitor of Rho kinase, 
resulted in a loss of phospho-MLC2 levels associated with stress fibers to levels 
similar to control cells.  These findings are consistent with the increased RhoA 
levels associated with loss of CCM2 expression.  Further, this suggests that 
there is increased signaling downstream of RhoA in CCM2 knockdown cells that 
can be reversed with the Rho kinase inhibitor Y-27632. 
 
CCM2 regulates endothelial cell migration   
 80
Knockdown of CCM2 led to increased stress fiber formation in brain 
endothelial cells.  In order to determine if this impacted cell migration, we 
performed wound healing assays.  Confluent monolayers of brain endothelial 
cells expressing GFP were wounded and imaged every 15 minutes for 16 hours.  
Cells expressing a control vector were capable of healing 50% of the wound; 
however, cells lacking CCM2 were significantly less capable of closing the wound 
in the same period of time (Figure 5.8A-B).  This is consistent with increased 
RhoA signaling, as cessation of RhoA signaling is necessary for cytoskeletal 
turnover and migration. 
 
Endothelial tubule formation and maintenance of a permeability barrier requires 
CCM2  
Consistent with an impairment of endothelial cell migration, knockdown of 
CCM2 expression markedly inhibits in vitro tubule formation in Matrigel of mouse 
embryonic endothelial cells (MEECs).  MEECs were used in the study because 
bEND.3 cells do not readily form tubules in vitro.  After 16 hours of culture on a 
Matrigel plug, MEECs expressing the pLKO.1 control vector were able to form a 
network of branched tubules, while cells lacking CCM2 expression were impaired 
in this function (Figure 5.9B).   
An in vitro endothelial permeability assay was used to determine if CCM2 
was also important for endothelial monolayer integrity.  HUVECs were used 
because of the strong permeability barrier formed by HUVEC monolayers.  
CCM2 knockdown in HUVECs resulted in increased permeability compared to 
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cells treated with the control siRNA (Figure 5.9A).  Furthermore, the CCM2 
knockdown HUVECs induced permeability to the extent that was comparable 
with control cells treated with EGTA to induce permeability.  Thus, CCM2 is 
required for proper endothelial cell functions including migration, morphogenesis, 
and permeability.  We hypothesize these defects are due in part to aberrant 
regulation of Smurf1-mediated degradation of RhoA. 
 
Discussion 
CCM is a disease of the vasculature of the central nervous system.  
However, the pathogenesis of CCM remains unclear.  Analysis of the amino acid 
sequence of the three genes known to be mutated in the familial form of CCM 
has not identified any catalytic domains.  This suggests that the function of these 
three proteins is to organize signaling complexes in the cell.  Indeed, we have 
acknowledged this role for CCM2 as an osmosensing scaffold for activation of 
the p38 MAPK pathway (Uhlik et al., 2003; Zawistowski et al., 2005).  It is now 
clear that scaffolding proteins play major roles in both the stimulus-dependent 
activation of a signaling cascade as well as the subcellular localization of the 
signaling module (Lu et al., 2006; Miller and Lefkowitz, 2001).  We have 
previously shown that the CCM2 PTB domain is responsible for localizing CCM1 
to the cytoplasm of cells (Zawistowski et al., 2005).  Our lab has shown further 
that the proteins EF1A1, RIN2, and tubulin also interact with CCM2 in a PTB-
domain dependent manner (Hilder et al., 2007).  How CCM2 is regulating the 
function of these proteins remains to be determined; however, the diversity of 
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binding partners suggests a complex and varied role for CCM2 in cell physiology.  
In our current work we provide evidence that CCM2 acts to recruit the E3 ligase 
Smurf1 to specific locations at the cell membrane to regulate localized 
degradation of RhoA.  Again, the PTB domain of CCM2 was necessary for this 
interaction.  What makes this phenomenon novel is the interaction of the CCM2 
PTB domain with the Smurf1 catalytic HECT domain.  To our knowledge this is 
the first example of a PTB-HECT domain interaction.  We have found that PTB 
binding motifs are conserved in many other HECT domains (Table 5.1) and this 
may be the first example of a yet unappreciated role for PTB domains. 
Although the CCM2 interaction with Smurf1 does not appear to change 
the catalytic activity of Smurf1 or act to recruit CCM2 as a Smurf1 substrate, this 
interaction does appear to play a role in localization of Smurf1 to the membrane 
to degrade RhoA.  Studies of NEDD4 E3 ligases have provided trends 
associated with the common domain architecture of these proteins.  The amino-
terminal C2 domain has been shown to be involved in membrane localization of 
NEDD4 family members.  This was first demonstrated in the Ca2+ dependent 
membrane localization of NEDD4 via its C2 domain (Plant et al., 1997).  The C2 
domain has also been implicated in an auto-inhibition of the HECT domain 
(Wiesner et al., 2007).  The majority of protein-protein interactions for NEDD4 E3 
ligases have been attributed to the WW domains.  Within this family, WW 
domains vary in number as well as primary sequence and are believed to be the 
source of substrate specificity (Ingham et al., 2005).  Furthermore, WW domains 
have been implicated in phosphorylation-dependent regulation of these proteins 
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(Gallagher et al., 2006).  Roles for intermolecular interactions within the HECT 
domain have been less clear, aside from the role of E2 binding to this region.  
However, Smad7, an inhibitory Smad in the TGF-beta signaling pathway, has 
been shown to interact with the HECT domain of Smurf1 and Smurf2 via the 
Smad7 N-terminal domain (NTD) and promote association of the Smurf1/2 HECT 
domain with the E2 (Ogunjimi et al., 2005).  A Smad7-Smurf1/2 interaction also 
occurs between a PY motif within Smad7 and the WW domains of Smurf1/2 
(Chong et al., 2006).  The MH2 domain of Smad7 binds to the TGF-beta receptor 
to recruit Smurf1/2 to the receptor and promote downregulation by ubiquitination 
of the receptor (Ebisawa et al., 2001).  Therefore, there is prior evidence for 
regulation of Smurf activity by localization.  In the case of CCM2, it appears that 
CCM2 may be recruiting Smurf1 to sites of actin remodeling in order to regulate 
the localized degradation of RhoA.   
It should be noted that there has been no evidence thus far that Smurf1/2 
are involved in CCM.  The initial characterization of Smurf1/2 was in the context 
of downregulation of the TGFβ signaling pathway.  Indeed, knock-out animal 
models for proteins at many levels of the TGFβ signaling pathway have displayed 
abhorrent vascular phenotypes (Arthur et al., 2000; Lebrin et al., 2005; Park et 
al., 2008).  Since CCM2 binds and localizes Smurf1, it then seems reasonable to 
believe that CCM2 may also be involved in regulation of TGFβ signaling.  In this 
way, the TGFβ signaling pathway may be relevant to CCM pathology.   
The significance of our work is, in part, the knockdown of CCM2 in a brain 
microvascular endothelial cell line, bEND.3.  Endothelial cells lacking CCM2 
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expression are defective in cell migration, permeability, and tubule formation.  
bEND.3 cells display an increase in RhoA abundance, predictably leading to 
increased signaling via the Rho kinase (ROCK) pathway.  Indeed, the importance 
of ROCK signaling in endothelial cells has been recognized.  Subsequent 
phosphorylation of MLC2 results in actomyosin contractility, loss of cell to cell 
contact, and increased permeability (Figure 5.10, (Wojciak-Stothard and Ridley, 
2002)).  We show that CCM2 knockdown leads to increased abundance of RhoA 
and stress fibers as well as increased phosphorylated MLC2 associated with 
stress fibers.  Further, co-expression of CCM2 and Smurf1 led to cell rounding, 
likely due to dramatic loss of RhoA and cytoskeletal collapse.  
Recent work has shown that CCM2 is a negative regulator of RhoA 
signaling in HUVECs (Whitehead et al., 2009); however, the molecular 
mechanism was not determined.  We also provide evidence for activation of this 
pathway, although we observed a decrease in directed cell migration in bEND.3 
cells, a response not observed with HUVECs.  This suggests variability in 
endothelial cell physiology between these two cell types.  Taken together, these 
studies strongly imply that defective RhoA regulation is a significant contributor to 
the pathogenesis of CCM.  
We now provide the mechanism of increased RhoA signaling associated 
with loss of CCM2.  For the first time we show that CCM2 associates with Smurf1 
to regulate the degradation of the GTPase RhoA.  Further, we have 
characterized a novel interaction between the CCM2 PTB domain and the 
Smurf1 HECT domain.  Although the CCM2 interaction with Smurf1 does not 
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regulate the catalytic activity of Smurf1 nor act to recruit CCM2 as a Smurf1 
substrate, this interaction plays a role in localization of Smurf1 to promote 
degradation of RhoA.   
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Figure 5.1:  Smurf1 binds CCM2, MEKK2, and MEKK3.  A) RAW264.7 stable cell 
lines expressing empty vector, Flag-CCM2, or Flag-CCM2 F217A were lysed and 
incubated with anti-FLAG-coated sepharose beads.  The associated endogenous 
Smurf1 was examined by western blot.  B) Cells expressing HA-tagged CCM2, 
MEKK2, or MEKK3 with Flag-Smurf1C699A were immunoprecipitated with anti-
HA antibody and associated Flag-Smurf1C699A was determined by western 
Blot.  C) The Smurf1-MEKK3 and Smurf1-CCM2 interaction is direct.  Purified 
GST or GST-Smurf1 was incubated with purified His-MEKK3 or His-CCM2 and 
associating proteins were determined by western blot using anti-MEKK3 antibody 
or anti-CCM2 antibody. 
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Figure 5.2:  CCM2 interacts with Smurf1 via a novel PTB domain – HECT 
domain interaction.  A) CCM2 interacts with the Smurf1 HECT domain.  Cells 
expressing HA-CCM2 with FLAG-Smurf1C699A, FLAG-Smurf1ΔHECT or FLAG-
Smurf1HECT were lysed and immunoprecipitated with anti-HA antibody.  The 
associating proteins were determined by western blot for anti-Flag antibody.  B) 
CCM2 interacts with Smurf1 in a PTB domain dependent manner.  Cells 
expressing FLAG-Smurf1C699A and CFP-CCM2 or CFP-CCM2 F217A were 
lysed and immunoprecipitated with anti-FLAG antibody.  Associated CFP-CCM2 
was determined by western blot for anti-GFP antibody.  C) CCM2 interacts with 
the Smurf1 HECT domain in a PTB domain dependent manner.  FLAG-
Smurf1HECT was expressed with either CFP-CCM2 or CFP-CCM2 F217A in 
cells.  Cell lysates were incubated with anti-Flag antibody and associating CFP-
CCM2 was determined by western blot.  D) CCM2 can associate with either 
Smurf1 or Smurf2.  Cells expressing HA-CCM2 and either FLAG-Smurf1C699A 
or FLAG-Smurf2C716A were lysed and immunoprecipitated with anti-FLAG 
antibody.  Associating HA-CCM2 was determined by western blot for anti-HA.  E) 
An NPYY motif within the HECT domain of Smurf1 is responsible for interaction 
with CCM2.  Cells expressing HA-CCM2 and FLAG-Smurf1C699A, FLAG-
Smurf1 N457A/Y460A/C699A, FLAG-Smurf1 P458A/Y460A/C699A, or FLAG-
Smurf1 Y459A/Y460A/C699A were lysed and immunoprecipitated with anti-
FLAG antibody.  Associated HA-CCM2 was determined by western blot.   
 88
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3:  CCM2 is not a Smurf1 substrate nor does it impact Smurf1 catalytic 
activity.  A) Cells expressing HA-CCM2, HA-MEKK2, Myc-RhoA, FLAG-Smurf1 
C699A, or FLAG-Smurf1 WT were lysed and steady-state levels of HA-CCM2, 
HA-MEKK2, or Myc-RhoA were determined by western blot.  B)  Cells expressing 
FLAG-Smurf1 C699A, FLAG-Smurf1 WT, or HA-CCM2 were lysed, and FLAG-
Smurf1 proteins were immunopurified.  The immunopurified FLAG-Smurf1 or 
FLAG-Smurf1 C699A was subsequently used for an in vitro ubiquitination assay.  
C)  Cells expressing FLAG-Smurf1 C699A, FLAG-Smurf1 WT or FLAG-Smurf1 
YY-AA were lysed and immunopurified for in vitro ubiquitination.   
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Figure 5.4.  Expression of Smurf1 WT and CCM2 leads to cell morphology 
changes.  A) COS-7 cells expressing HA-CCM2, FLAG-Smurf1 WT, or FLAG-
Smurf1 YY-AA were fixed and stained with anti-HA antibody or anti-FLAG 
antibody.  B) COS-7 cells expressing HA-CCM2 and Smurf WT display cell 
rounding (arrow), while cells expressing HA-CCM2 and FLAG-Smurf1 YY-AA (C) 
or HA-CCM2 and FLAG-Smurf1 C699A (D) do not.  CCM2 can recruit the Smurf1 
HECT domain to the plasma membrane.  E) The Smurf1 HECT domain does not 
localize to the plasma membrane.  CCM2 recruits the Smurf1 HECT domain to 
the plasma membrane.  COS-7 cells expressing HA-CCM2, FLAG-Smurf1 
C699A, or FLAG-Smurf1 HECT were fixed and stained with anti-FLAG and anti-
HA antibodies. 
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Figure 5.5:  CCM2 regulates Smurf1-mediated RhoA abundance.  A) bEND.3 
cells expressing pLKO.1 or CCM2 shRNAs were lysed and abundance of 
endogenous RhoA, Rac1, MEKK2, and MEKK3 were analyzed by western blot.  
Erk2 was measured as a loading control.  Fold change was calculated by 
determining the RhoA intensity relative to the Erk2 intensity for that sample 
standardized to the RhoA/Erk2 ratio for cells expressing pLKO.1.  The line 
denotes where lanes were removed for clarity.  B) HEK293 cells were transfected 
with Myc-RhoA, FLAG-Smurf1 WT, FLAG-Smurf1 C699A, and increasing 
amounts of HA-CCM2.  Cells were subsequently lysed and analyzed by western 
blot.  C) Relative quantitation of CCM2 RNA expression in bEND.3 cells was 
determined by real time RT-PCR quantitation.  Representative data shown.  
CCM2 RNA levels were standardized to β-actin RNA levels.  D)  Relative 
quantitation of RhoA RNA expression in bEND.3 cells was determined by real 
time RT-PCR quantitation.  Representative data shown.  RhoA RNA levels were 
standardized to β-actin RNA levels.   
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Figure 5.6:  CCM2 knockdown leads to cytoskeletal changes in brain endothelial 
cells.  bEND.3 cells stably expressing pLKO.1 or CCM2 shRNA were plated on 
Matrigel-coated coverslips and stained for phalloidin (red), phospho(Ser19)-
MLC2 (green) and DAPI (bule).   
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Figure 5.7:  Increased association of phospho-MLC2 with stress fibers in CCM2 
knockdown cells is abrogated with treatment with the ROCK inhibitor Y-27632.  
Top: bEND.3 cells grown on coverslips were treated with or without Y-27632 for 
24 hours and then stained for phospho(Ser19)-MLC2.  Bottom: Intensity of 
phosphorylated MLC-2 associated with rhodamine-phalloidin was determined as 
described in Materials and Methods.   
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Figure 5.8:  Loss of CCM2 expression impairs directed cell migration.  A) bEND.3 
cells grown to confluency were subjected to an in vitro wound healing assay.  
Cells were imaged every 15 minutes for 16 hours.  The paths taken by cells 
(green) expressing either pLKO.1 or CCM2 shRNAs demonstrates decreased 
migration in CCM2-knockdown cells.  The cell’s starting point is shown in blue 
and its final location is shown in red.  B) Quantitation of in vitro wound healing 
assays.  Cells lacking CCM2 expression are less able to close a wound as 
measured by percent wound closure.  * p < 0.02 
A.
B.
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Figure 5.9:  CCM2 is necessary for endothelial barrier function and endothelial 
tubule formation.  A) HUVECs electroporated with either CCM2 SMARTpool 
siRNA or scrambled siRNA were plated on duplicate Matrigel-coated Transwells 
and were allowed form monolayers for 48 hours.  The medium was then removed 
and replaced with EBM-2 containing 0.625 mg/mL FITC-dextran, with or without 
4 mM EGTA.  Aliquots (50 μL) were removed from the bottom well at 15 minute 
increments for 1.5 hours and fluorescence was read using a PHERAstar 
microplate reader.  Data is expressed as the change in relative fluorescence 
units (RFU) per minute ± the standard deviation of the duplicates.  Results are 
representative of three experiments.  The average percent knockdown of CCM2 
RNA levels compared to scrambled controls was ~60%.  B)  Mouse embryonic 
endothelial cells stably expressing either pLKO.1 or CCM2 shRNA were 
subjected to an in vitro tube formation assay as described in Materials and 
Methods.  
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Table 5.1:  The NPXY motif in the Smurf1/2 HECT domain is conserved in other 
human HECT domains.  
Accession Protein Motif Residues 
O00308 WWP2 NPMY 573 - 576 
Q8IYU2 HACE1 NPDY 610 - 613 
Q76N89 HECW1 NPYY 1317-1320 
Q15034 HERC3 NPIY 760-763 
Q6ZTQ5 Similar to NEDD4L NPMY 134-137 
Q96PU5-3 NEDD4L isoform 3 NPYY 573-576 
Q96PU5-5 NEDD4L isoform 5 NPYY 657-660 
Q15751 HERC1 NPYY 3030-3033 
Q9HCE7-2 SMURF1 isoform2 NPYY 431-434 
O95071 UBR5 NPLY 539-542 
Q96PU5 NEDD4L NPYY 677-680 
Q96J02 ITCH NPMY 606-609 
Q9P2P5 HECW2 NPYY 1284-1287 
Q9H0M0 WWP1 NPMY 625-628 
NP_940682 NEDD4 isoform 2 NPYY 949-952 
P46934 NEDD4 NPYY 702-705 
Q9HCE7 SMURF1 NPYY 457-460 
Q9HAU4 SMURF2 NPYY 451-454 
CAI42354 HUWE1 NPMY 4075-4078 
CAI17960 ITCHY homolog NPMY 565-568 
Q9H0M0-3 WWP1 isoform 3 NPMY 495-498 
Q96PU5-2 NEDD4L isoform 2 NPYY 613-616 
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Figure 5.10:  Model of CCM2-Smurf1 function.  CCM2 recruits Smurf1 to specific 
locations at the plasma membrane to promote RhoA ubiquitination and 
degradation.  This complex of CCM2 and Smurf1 therefore acts as a negative 
regulator of signaling downstream of RhoA.  In the absence of CCM2, increased 
abundance of RhoA leads to enhanced RhoA signaling.  RhoA signaling causes 
activation of ROCK and MLC2, resulting in actomyosin contractility and stress 
fiber formation.  In endothelial cells, this leads to increased permeability and 
decreased cell to cell contact through VE-cadherin.   
 
VI.  Conclusion 
Recent advancements 
Our knowledge of CCM pathogenesis and CCM protein function has been 
recently expanded due to many high quality CCM research publications.  Within 
the past four months, the two hit hypothesis has been proven, multiple CCM 
vertebrate models have been characterized, and a receptor upstream of CCM 
proteins has been described.  The field has taken a large step forward and the 
recent developments are described below. 
The two hit hypothesis of CCM pathogenesis had long been suspected, 
but not proven.  Due to high expression levels of CCM mRNA in neural cells and 
the specificity of CCM lesions to the brain, parenchymal cell involvement was still 
considered relevant to CCM pathogenesis.  A recent publication by Akers et al 
has shown that endothelial cells are responsible for CCM pathogenesis due to 
the two hit hypothesis.  This study sequenced CCM1, CCM2, and CCM3 from 
endothelial and surrounding cells from CCM lesions.  In addition to the familial 
mutations in CCM1, CCM2, or CCM3, endothelial cells from CCM lesions had a 
second somatic mutation in these genes.  These somatic mutations were not 
found in the surrounding neural tissue.  Therefore, bi-allelic mutations in CCM1, 
CCM2, or CCM3 leading to complete loss of expression in endothelial cells 
appear to be the cause of CCM lesion formation (Akers et al., 2009).   
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Conditional knockout mouse models have confirmed that endothelial cells 
are the tissue responsible for CCM endothelial cell dysfunction.  Two 
independent groups generated CCM2 conditional knockout models to examine 
the role of endothelial and neural cells in embryonic lethalities associated with 
loss of CCM2.  In both studies, loss of CCM2 in the neuroepithelium did not lead 
to embryonic lethality.  Loss of CCM2 expression in endothelium led to 
embryonic lethalities due to vascular defects.  Interestingly, these endothelial 
conditional knockout models both phenocopied the CCM1 and CCM2 gene-trap 
models.  Loss of CCM2 in endothelial cells led to defects in aortic development.  
The aortic arch was of an inconsistent diameter and was collapsed in some 
regions.  Impaired invasion of the embryonic vasculature into the labyrinth layer 
caused aberrant placenta vascularization.  CCM2 knockdown endothelial cells 
had impaired tube lumen formation in vitro and increased RhoA activation.  Loss 
of CCM2 expression caused increased VEGF-induced permeability, which could 
be blocked with simvastatin.  The authors demonstrated that simvastatin blocked 
the increased signaling downstream of RhoA in CCM2 siRNA treated cells, 
suggesting that simvastatin should be further examined as a potential treatment 
for CCM2 patients (Boulday et al., 2009; Whitehead et al., 2009).  Based on 
these studies and the work presented in this dissertation, regulation of RhoA 
signaling in endothelial cells appears to be a critical function for CCM2.   
The signaling events upstream of the CCM protein complex have 
remained elusive.  A recent study has identified a receptor that provides a 
function for the CCM1/CCM2 protein complex.  The heart of glass (HEG1) 
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receptor was identified in a zebrafish screen for cardiovascular defects.  It was 
hypothesized that this receptor may be in the same pathway as CCM1 and 
CCM2 as loss of HEG1 expression in zebrafish led to cardiovascular defects that 
phenocopied santa and valentine embryos.  Loss of HEG1 in mice led to 
pulmonary hemorrhage and dorsal aorta collapse.  The endothelial cell junctions 
in HEG1-null animals were found to be compromised compared to wild type 
mice.  On a molecular level, HEG1 was found to associate with CCM2 through 
CCM1.  The authors concluded that HEG1 is the receptor upstream of the CCM 
protein complex and this signaling pathway is necessary for blood vessel 
morphogenesis and integrity (Kleaveland et al., 2009). 
The studies presented in this dissertation agree well with these recent 
advancements in our knowledge of CCM.  We characterized a CCM1/CCM2 
protein complex and predicted that it was relevant for CCM pathology.  We now 
know that this interaction is important for signaling through the HEG1 receptor 
(Kleaveland et al., 2009).  Signaling through this pathway appears to be critical 
for vascular development and integrity.  We also showed that CCM2 is necessary 
for osmotic activation of p38, which is necessary for vascular development.  Our 
examination of the CCM2-Smurf1 interaction characterized the molecular 
mechanism for enhanced RhoA activation in CCM2 knockdown cells (Whitehead 
et al., 2009).  CCM2 recruits Smurf1 to the membrane, leading to RhoA 
degradation and downregulation of RhoA signaling.  This maintains the proper 
cytoskeletal turnover in endothelial cells to allow migration and to enhance cell-
to-cell contacts.  Our study of CCM2 function in zebrafish showed that CCM2 is 
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necessary for aorta morphogenesis and proper embryonic blood flow, which is 
consistent with mouse and zebrafish models utilized by other groups.  We can 
therefore appreciate the importance of this work in the context of CCM research 
and also endothelial cell physiology.   
Based on our current knowledge of CCM proteins, we can begin to 
envision how these proteins may function in endothelial cells and how loss of 
CCM1, CCM2, or CCM3 could lead to endothelial defects (Figure 6.1).  CCM1 is 
a Rap1 effector that is recruited to tight junctions to maintain junctional integrity.  
It also serves as an adaptor to link CCM2 to the HEG1 receptor.  In the absence 
of CCM1, endothelial tight junctions are compromised, leading to endothelial 
leakiness.  CCM2 coordinates activation of p38 via MEKK3 signaling, which is 
necessary for proper embryonic vascular development.  CCM2 also recruits 
Smurf1 to specific sites at the plasma membrane to promote RhoA degradation.  
In the absence of CCM2, RhoA signaling is enhanced, leading to increased 
actomyosin contractility and stress fiber formation, which decreases cell-to-cell 
contact and prevents cell migration.  In this way, loss of CCM1 or CCM2 could 
lead to endothelial cell defects that phenocopy each other, but these defects 
could occur through distinct mechanisms.   
 
Future directions 
We are only at the beginning of our understanding of the function of the 
proteins associated with cerebral cavernous malformations.  The roles of CCM1, 
CCM2, and CCM3 biochemically and in vivo are still largely uncharacterized.  
 101
The work presented in this dissertation has led to new questions about CCM 
proteins and how dysregulation of these proteins could lead to cerebral 
cavernous malformations.   
The heart of glass (HEG1) receptor has emerged as a component of the 
CCM complex.  HEG1 has been linked to CCM both genetically and 
biochemically.  CCM1 interacts with the cytoplasmic tail of the HEG1 receptor, 
linking it to CCM2.  However, the signaling events downstream of HEG1 are 
completely uncharacterized.  Based on what we know about CCM1 and CCM2 
function, there are multiple pathways that could be involved in HEG1 signaling.  
First, HEG1 could signal through CCM1 to regulate CCM1 association with 
ICAP1, Rap1A, and β-catenin.  In this way, HEG1 could be involved with Rap1A 
or β-catenin signaling pathways.  HEG1 could also signal through CCM2 through 
MEKK3-medated p38 activation.  Finally, we have characterized CCM2 as a 
negative regulator of RhoA signaling through Smurf1-mediated degradation.  
Thus, HEG1 could facilitate this pathway as well.  Alternatively, activation of 
HEG1 may activate another signaling pathway not known at this time to be linked 
to CCM proteins.  It is clear that significant effort is needed to characterize the 
signaling pathways downstream of HEG1 and how disruption of these pathways 
could contribute to CCM pathogenesis. 
Smurf1-mediated degradation of RhoA has been characterized as a 
mechanism for regulation of cell polarity.  In response to activation of the TGFβ 
receptor, Smurf1 associates with the Par6-PKC zeta cell polarity complex to 
regulate localized degradation of RhoA.  In epithelial cells, the localized 
 102
degradation of RhoA leads to dissolution of tight junctions and epithelial-
mesenchymal transition (EMT).  In the work presented here, we have 
demonstrated that CCM2 binds Smurf1 to regulate Smurf1 localization and 
degradation of RhoA in endothelial cells.  However, a role for CCM2 in cell 
polarization has not been examined.  Therefore, a future direction of this project 
is to examine the role of CCM2 in regulating cell polarity, both in epithelial cells 
and endothelial cells.   
CCM1, CCM2, and CCM3, have been shown to associate with each other 
and with proteins outside the CCM protein complex.  We hypothesize that CCM1, 
CCM2, and CCM3 work together as a CCM protein complex but also have 
distinct roles with individual effectors.  An important avenue of research is to 
understand the mechanisms involved with CCM complex association and 
dissociation.  Using a combined approach of immunopurification of endogenous 
CCM protein complexes, size-exclusion chromatography, and mass 
spectrometry, the composition of CCM protein complexes within the cell would be 
determined.  CCM protein complexes and the interactions regulating these 
complexes would provide significant insight into the signaling roles of CCM1, 
CCM2, and CCM3.   
The findings presented in this dissertation indicate that CCM2 regulates 
multiple protein complexes and signaling pathways important in endothelial cell 
function.  Analysis of these signaling pathways has provided insights into the 
molecular mechanisms that could be involved in cerebral cavernous 
malformation pathogenesis.  These developments in our understanding of the 
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function of CCM2 will hopefully continue to advance the field toward the goal of 
targeted therapies for cerebral cavernous malformations. 
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Figure 6.1:  Model of CCM protein signaling complexes in endothelial cells.  
CCM1, CCM2, and CCM3 associate as a multi-protein complex.  CCM1 functions 
to link HEG1 to CCM2, and presumably CCM3.  CCM2 activates p38 signaling 
through MEKK3, which regulates vascular development.  CCM2 can also 
associate with Smurf1 to regulate RhoA degradation.  This pathway decreases 
signaling through RhoA and facilitates migration and cell contact maintenance.  
Finally, CCM1 can associate with ICAP1 and Rap1A to promote tight junction 
integrity.  Absence of one or more of these pathways may be important in CCM 
pathogenesis.   
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